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TDP-43 pathology is a disease hallmark that characterizes both sporadic and 
familial amyotrophic lateral sclerosis (ALS) and frontotemporal lobar 
degeneration (FTLD-TDP). TDP-43 has been implicated in transcription, RNA 
metabolism and transport, and different TDP-43 post-translational modifications, 
spanning from phosphorylation to acetylation, can regulate its activity. In the 
present PhD thesis we provide evidences that TDP-43 interacts with histone 
deacetylase 1 (HDAC1), both in vivo and in vitro. By biochemical assays, 
performed in SH-SY5Y cells, we demonstrated that HDAC1, as well as HDAC6, can 
modify TDP-43 acetylation, that occurs mainly on amino acid residues K142 and 
K192, located in the RRM1 and RRM2 domains, necessary for the interaction . 
Interestingly, HDAC1 overexpression modulates TDP-43 transcriptional activity 
on CHOP promoter, but not TDP43 splicing activity on polymerase delta 
interacting protein 3 [POLDIP3] gene. Finally, both in cell culture and in 
Drosophila, HDCA1 reduced level (genomic inactivation or siRNA) or treatment 
with pan-HDAC inhibitors, reduce WT or pathological mutant TDP-43 toxicity, 
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1. Amyotrophic Lateral Sclerosis (ALS) 
1.1 Epidemiology 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterised by 
progressive muscular paralysis reflecting degeneration of motor neurones in the primary 
motor cortex, brainstem and spinal cord.  
The word "Amyotrophy" refers to the atrophy of muscle fibres, which are denervated as 
their corresponding anterior horn cells degenerate, leading to weakness of affected 
muscles and visible fasciculations; on the other hand "Lateral sclerosis" refers to 
hardening of the anterior and lateral corticospinal tracts, as motor neurons in these areas 
degenerate and are replaced by gliosis1. The death of motor neurons is associated with 
the activation of astrocytes, microglia and intracellular accumulation of ubiquitinated 
skein-like inclusions in the axons and cell bodies of the remaining atrophic motor 
neurons2. This leads to generalised fasciculations, muscle weakness, speech and 
swallowing disabilities, muscle atrophy, progressive paralysis and, ultimately, death 
caused by respiratory failure.  
The crude prevalence of ALS is estimated at 4–6/100,000 population. The prevalence of 
ALS increases with age, reaching a peak in the 60–75 years old age-group at 33/100,000 
for men and 14/100,000 for women3,4. The incidence rate of ALS is 1–3/100,000 person 
year and increases with age. A peak incidence rate of 10.5 and 7.4/100,000, in males and 
females, respectively, is observed in the 55–75 years old age-group; these values are 
three times higher in Sardinian population5. In fact Sardinia, the second largest 
Mediterranean island, represents a genetic isolation characterized by a higher frequency 
of ALS cases, in particular associated with TARDBP A382T mutation6,7 
ALS is a multifactorial pathology caused by both genetic and environmental factors. 
Degeneration of motor neurons is driven by the alteration of molecular processes 
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axonal dysfunction, lack of fundamental growth factors underlying normal neuronal 
trophic development and alteration of calcium and glutamate loading processes. 
 
1.2.Genetic factors 
The idea of the involvement of genetic factors in the development of the disease has 
ancient origins, in fact pathological cases with family history and inheritance have been 
observed as early as 18508. Although most cases are classified as sporadic ALS (sALS), 
about 10% some cases of ALS are inherited, and therefore classified as familial cases 
(fALS), with multiple autosomal dominant and recessive forms. The sporadic and familial 
ALS shares clinical and neuropathological manifestations, and both types of patients, 
show a certain degree of heterogeneity regarding the symptoms, age of onset and 
duration of the disease. All the genes found mutated in fALS cases were found mutated in 
sALS2,9. Since fALS and sALS are clinically indistinguishable, with the exception of the time 
of the onset of the disease, that is found to be earlier in cases of family ALS1, several 
studies have been carried out in order to understand the role of genes associated with 
fALS in sporadic cases. 
 
Figure 1. Known genetic causes in familial and sporadic ALS. Most ALS cases are sporadic (sALS) and only 
10% are inherited, called familial (fALS). (A) 20% of fALS are caused by mutations in SOD1, which is the first 




Over the years, a number of investigations have been carried out, leading to the 
identification of a large number of genetic factors associated with ALS (Table 1), which are 
categorized according to the risk of developing the disease in two large groups: 







 Simona Sanna: “Epigenetics and neurodegeneration: physiological relevance of TDP-43/HDAC1 interaction”. 
Ph.D. Course in Life Sciences and Biotechnologies – University of Sassari. 
 
  
TARDBP, C9ORF72, UBQLN2, which are by no chance the ones that are most 
frequently mutated in pathologic subjects; 
• low-risk sALS, so-called susceptibility factors such as NEFH11 (Table 1); 
Up to now, about 20 genes explain most of the cases of familial sALS, but only a minority, 
about 10%, of sporadic cases of illness12,13. 
LOCUS GENE, PROTEIN Disease Mechamism ONS
ET 
AD/AR 
ALS 1 SOD1, Cu/Zn SOD1 Oxidative stress A AD/AR 
ALS 2 ALS2, Alsin Endosomal trafficking J AR 
ALS 3 ? -- A AD 
ALS 4 SETX, Senataxin RNA metabolism J AD 
ALS 5 SPG11, Spatacsin DNA damage repair 
and axon growth 
J AR 
ALS 6 FUS, Fused in sarcoma RNA metabolism, 
DNA repair 
J/A AD/AR 
ALS 7 ? -- A AD/AR 
ALS 8 VAPB, Vescicle-associated membrane Endoplasmatic 
reticulum stress 
A AD 
ALS 9 ANG, Angiogenin RNA metabolism A AD 
ALS 10 TARDBP, TAR DNA-binding protein RNA metabolism A AD 
ALS 11 Phosphoinositide-5-phosphatase Endosomal trafficking A AD 
ALS 12 OPTN, Optineurin Autophagy A AD/AR 
ALS 13 ATXN2, Ataxin 2 RNA metabolism A AD 
ALS 14 VCP, valosin-containing protein Autophagy A AD/AR 
ALS 15 UBQLN2, Ubiquilin 2 UPS 
(ubiquitin-
proteasome system) 
and Autophagy  
J/A X-linked 
ALS 16 SIGMAR1, sigma non-opioid 





ALS 17 CHMP2B, Charged multivesicular 
body protein 2B 
Endosomal trafficking A AD 
ALS 18 PFN1, Profilin 1 Cytoskeleton A AD 
ALS 19 ERBB4, Neuregulin-ErbB4 Neuronal 
development 
A AD 
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ALS 21 MATR3, Matrin 3 RNA metabolism A AD 
ALS 22 TUBA4A, Tubulin a4A Cytoskeleton A AD 
ALS-FTD1 C9orf72, guanine nucleotide 
exchange C9orf72 








ALS-FTD3 SQSTM1 , sequestosome 1 Autophagy A AD 
ALS-FTD4 TBK1, serine/threonine-protein 
kinase TBK1 
Autophagy A ? 
Susceptibil
ity factors 
PRPH, peripherin gene Cytoskeleton - - 
Susceptibil
ity factors 






NEFH, Neurofilament Heavy 
Polypeptide 
Cytoskeleton - - 
 
Table 1.Principal gene locus involved in ALS and relative mutations: Genetic factors at the base of the SLA. 
Abbreviations: AD: dominant autosomal; AR: autosomal recessive; A: adult; J: youthful. (Data extracted from 
OMIM database: http://omim.org/phenotypiSeries/105400). 
Superoxide dismutase 1 (SOD1) is the first ALS-linked gene that was identified in 199314 
and, for almost fifteen years, ALS research has been focused on mutant forms of this 
protein15,16. Since 2008, starting with the discovery of ALS-linked mutations in 
DNA/RNA-binding proteins TDP-43 and FUS, an era of unprecedented genetic discoveries 
in ALS begun.  
Although the genetic cause of most sALS is not known, recent studies have shown that 
mutations causing fALS are also able to cause illness in sporadic cases. In fact, only a small 
part of sALS patients showed that they had de novo mutations in known ALS-causing 
genes17-20. C9ORF72 repeat expansions, which were also found in a substantial fraction 
(~7%) of apparently sporadic ALS patients, most likely are not occurring de novo21,22, but 
rather represent cases with insufficient family history or incomplete penetrance. Taken 
together, ~10% of apparently sporadic ALS cases are caused by known genetic mutations, 
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The pathological hallmark of ALS is the presence of ubiquitin-positive inclusions, 
consisting of misfolded protein aggregates in affected motor neurons and glial cells of the 
spinal cord and motor cortex. The most frequent protein component of these inclusions, 
in most ALS cases, is TDP-4323,24. Notable exceptions are patients with mutations in SOD1 
and FUS, which lack TDP-43 inclusions, but show misfolded SOD125,26 or FUS27,28 protein 
accumulations. Moreover, patients with C9ORF72 expansions are affected by the most 
complex pathology form, characterized by typical TDP-43 inclusions, atypical TDP-43 
negative inclusions29-31, consisting in abnormal dipeptide proteins32,33, as well as nuclear 
repeat RNA foci29,32,34 (figure 2 and 3). 
ALS-associated genes code for proteins implicated in different cellular processes, and 
various mechanisms have been suggested as major contributors to neurodegeneration in 
fALS and sALS35. 
There are two typical expressions of the onset of the disease: about 70% of patients 
present limb atrophy and muscular weakness at the trunk level at the initial stage of the 
disease , while the rest of the patients exhibit a symptomatology that ,during the first 
stage of the pathology, affects musculature of the tongue and swallowing36. Nearly 85% 
of patients with spinal-onset ALS, however, exhibit bulbar changes with disease 
progression. Approximately 50% of all patients diagnosed with ALS show cognitive and 
language impairment, while 10% of patients have clear signs of Frontotemporal dementia 
(FTD). 
Some chromosomal loci containing ALS-causing genes are inherited as dominant while other as 
recessive autosomal traits, and it can be seen that there are at least 4 chromosome loci 
containing genes predisposing the pathology (Table 1). For the majority of ALS subtypes, the onset 
period is adulthood, with the exception of subtypes ALS2, ALS4, ALS5, whose period of onset is 
strictly juvenile. 
 
1.3 Environmental and lifestyle factors 
Environmental factors may play a decisive role in the onset of ALS disease. Among these 
risk factors the exposure to pesticides, fertilizers and heavy metals (such as selenium and 
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(farmers, foundry workers)37. Exposure to secondary metabolites of cyanobacteria38, such 
as non-neurotoxic amino acid β-N-methylamino-L-alanine (BMAA), may also have a 
primary role as a possible causative agent of ALS39. Cigarette smoking would appear to be 
an etiologic agent, with a directly proportional association between exposure time and 
exposure intensity40. Exposure to this set of chemical substances would result in cellular 
oxidative stress phenomena, increasing levels of reactive oxygen (ROS) and blood species 
in cerebral tissue, yielding to progressive neurodegeneration41. It also seems that, among 
all environmental factors, alcohol abuse42, excessive physical activity and mechanical 
trauma associated with it43, self-immunity phenomena, as well as latent infections 
mediated by retrovirus and enterovirus44, play a key role in the onset of ALS. In fact, this 
disease, has been reported at a higher frequency among groups of athletes with respect 
to general population, although it is unclear whether physical activity is a risk factor or is 
simply a marker of underlying athletic prowess45. 
 
2. Pathogenic mechanisms in ALS 
ALS is a heterogeneous disease, to which great diversity in genetic and environmental 
causes correspond a complex network of molecular pathogenic mechanisms that haven’t 
been completely understood yet. Nevertheless neuropathological hallmark of disease is 
the aggregation and accumulation of ubiquitinated proteinaceous inclusions in motor 
neurons. 
ALS pathogenic mechanisms, studied in many different experimental models and 
confirmed in ALS patients, outline a complex model in which non-competing mechanisms, 
including not only gene mutations and environmental factors but also impairment of 
protein homeostasis, aberrant RNA metabolism, impaired DNA repair, oxidative stress, 
mitochondrial dysfunction, dysregulation of nucleocytoplasmic and endosomal transport, 
neuroinflammation, excitotoxicity, axonopathy, are likely to converge in various 
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Figure 2. Molecular mechanisms of motor neuron injury in ALS. ALS is a complex disease involving 





2.1 Impaired protein homeostasis 
Pathological protein aggregates, identified as compact or skein-like ubiquitinated 
inclusions, are a cardinal feature of ALS48-50. The identification of TDP-43 as the most 
abundant protein constituent of these inclusions, initiated a major shift in our 
understanding of the pathobiology of ALS23. Under normal conditions, TDP-43 is 
predominantly localized in the nucleus, and loss of nuclear TDP-43 staining is seen in 
nearly all cells containing TDP-43-positive cytoplasmic inclusions23. TDP-43 inclusions are 
not restricted to motor neurons, and it seems that cytoplasmic redistribution of TDP-43 is 
an early pathogenic event in ALS. In 2008, when mutations in TARDBP, the gene encoding 
for TDP-43, were discovered in several fALS pedigrees, the evidences for TDP-43 
dysfunction in ALS were consolidated, thus establishing this protein as a crucial player in 
both sporadic and familial disease51. 
Although TDP-43 is the most abundant component of protein inclusions in 97% of ALS 
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the heterogeneity of the disease (Figure 3). 
 
 
Figure 3: Pathogenic hallmarks of ALS and the underlying factors and mechanisms.  
(A) In the majority of ALS cases, including all sporadic and most familial cases, the ubiquitinated inclusions 
contain TDP-43. When TDP-43 accumulates in the cytoplasm, it is excluded from the nucleus, where it 
normally resides in healthy cells. (B) In 0.5% of fALS that carry mutations in FUS, the cytoplasmic inclusions 
do not contain TDP-43, but they contain FUS protein. Similar observations to that of TDP-43, with partial 
nuclear clearance of FUS suggest that its neurotoxity may be the result of either loss of function or gain of 
toxicity. (C) In fALS patients with SOD1 mutations, misfolded SOD1 accumulates and becomes toxic to 
neurons. (D) In contrast, patients with hexanucleotide repeat expansions in C9ORF72 show typical TDP-43, 
similar to those found in sALS. (E) In addition to TDP-43 and DPR pathology, C9ORF72 patients accumulate 
nuclear RNA foci that contain sense and antisense hexanucleotide repeats in neuronal and glial cells. Insert 




SOD1 inclusions are found in motor neurons of patients with fALS, as well as in mouse 
and cellular models expressing SOD1 mutations52. Monoclonal antibodies that are specific 
for epitopes of misfolded SOD1, very common in inclusions motor neurons of patients 
with SOD1 fALS53, and seem to form similar structures in some patients with sALS54. 
Similarly, cytoplasmic inclusions containing mutant fused in sarcoma (FUS) protein have 
been observed in some patients with FUS-related fALS55,56. Proteins found in aggregates 
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TDP-43 and/or aggregation of the protein in cytoplasmic inclusions, may be key of 
pathogenic processes in both sALS and fALS. 
Protein misfolding and aggregation, in ALS, indicate both a defect in the activity of protein 
quality control (PQC) system, which includes molecular chaperons that lead protein 
folding and aggregation, and degradation systems (proteasome and autophagy). In fact, 
many ALS causing genes code for proteins that can promote dysfunction of the UPS 
(ubiquitin-proteasome system) such as SOD1, TDP-43 and VAPB, or proteins that are key 
regulators of both autophagy initiation, such as C9orf72 and optineurin, and execution, 
such as SQSTM1 and TBK1. 
 
2.2 Oxidative stress 
Several studies focused their attention on the role of mitochondria in the pathogenesis of 
neurodegenerative diseases such as ALS57. Mitochondrial dysfunctions, such as abnormal 
mitochondria and morphological defects, have been identified in skeletal muscles and 
intramuscular nerves of sALS patients58,59. In these cases, biochemical analysis revealed 
defects in muscular respiratory chain (complexes I and IV)60, which leads to/evolves/ends 
in (occhio a quale scegli per lasciare o togliere in) damage to motorneuron metabolism 
and alteration to mitochondrial membrane pores permeability, and high levels of 
mitochondrial calcium in muscle and spinal cord61. In transgenic mice, the main evidence 
of mitochondrial alteration is the presence of mitochondria with vacuoles. For example, in 
SOD1 G93A mice, there have been observed vacuous originated from the detachment 
between the internal and external mitochondrial membranes, leading to a remarkable 
increase in number and volume as pathology progresses62-64. 
The expression of mutated SOD1 in neuronal cell lines or in primary motor neuron 
cultures, causes depolarization of mitochondria, alteration of calcium homeostasis and 
reduces ATP production, similarly as it happens in SOD1 G93A transgenic mice65-67. 
Mitochondrial alterations may contribute to the generation of oxidative stress conditions, 
as they appear to mediate cell death by releasing calcium into the cytoplasm and by 
weakening the respiratory chain, leading to the release of cytochrome-c and pro-
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Oxygen is essential for life, but paradoxically, as a sub-product of its metabolism produces 
reactive oxygen species (ROS), which causes oxidative stress. Post-mortem analysis on 
brain tissues of patients with neurodegenerative diseases, such as ALS, clearly indicates 
an increase in the ROS index, in brain regions affected by the disease. The role of 
oxidative stress, and consequently of ROS in the onset of ALS, is still being discussed, 
since it is not clear yet whether they are the cause or a consequence of neuronal cell loss. 
However, ROS contribution to the events associated with neurodegeneration is evident70. 
Oxidative stress, in addition to mitochondrial damage, may be associated with an 
aberrant chemistry of SOD1. This appears to be a consequence of alterations in the shape 
of the active site that allow copper to interact with atypical substrates. In fact, modified 
SOD1, in contrast to normal activity, can act as peroxidase, resulting both in production of 
hydroxyl radicals and in inactivation of the enzyme itself, or can react with peroxynitrite 
causing tyrosine nitration71. Both peroxynitrite and hydroxyl radicals are strongly reactive 
species and can, therefore, cause oxidative damage to proteins, lipids, and DNA. 
Such damage can cause alteration of protein conformation, destruction of the active site 
of enzymes, and modification of cell membrane properties by oxidation of unsaturated 
fatty acids and introduction of DNA mutations72. While earlier this mechanism was 
referable only to aberrant mutations of SOD1, recent studies investigate the possible 
involvement of FUS and TDP-43: it appears that TDP-43 mutations may be responsible for 
the production of reactive oxygen species and may alter the functioning of the 
mitochondrial respiratory chain73. The sum of these events seems to be directly 
correlated to motorneurons degenerative process in patients with ALS. 
 
2.3 Aberrant RNA metabolism 
Many different RNA-binding proteins (RBPs) have been implicated in human diseases, 
ranging from cancer to neurodegeneration, and alteration of mRNA processing is a key 
event in ALS pathogenesis. There are more than one hundred genes associated with 
ALS74, a handful of which encode proteins that control RNA processing; table 1 reports 
RBPs known to be mutated in ALS patients. 
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A2/B1 are structurally similar, as they contain two RNA recognition motifs (RRMs) and a 
Gly-rich C-terminal domain75. FUS, EWSR1 and TAF15, which form the FET family, share a 
similar structure: a zinc finger and RRM domain that facilitates DNA and RNA binding, 
respectively, an N-terminal low complexity, prion-like domain that mediates protein 
interactions and self-assembly76-78, multiple C-terminal Arg-Gly-Gly (RGG) domains that 
facilitate non-specific RNA binding and protein interactions, and an atypical Pro-Tyr 
nuclear localization signal (PY-NLS) that is recognized by transporters that control 
nuclear–cytoplasmic shuttling79. Those proteins are predominantly multifunctional 
nuclear proteins widely expressed in most cell and tissue types, since they are implicated 
in a broad range of cellular processes. 
Whether motorneuron damage is caused by loss of normal nuclear function of TDP-43 
and FUS in RNA processing, or by toxic gains of function, or both is unknown79. TDP-43 
and FUS contain two RNA recognition domains—structures that are common to many 
RNA-interacting proteins, including those that are involved in mRNA transport. TDP-43 
and FUS may form part of such RNA transport complexes and, when mutated, could 
thereby contribute to motor neuron injury through loss of axonal mRNA transport. 
Fibroblast cell lines derived from patients with TARDBP-related ALS, showed the expected 
loss of nuclear expression of TDP-43, together with widespread changes in RNA splicing, 
including changes in transcripts of other RNA-processing genes and genes that have been 
previously implicated in ALS; hence, splicing disruption associated with the loss of nuclear 
TDP-43, is likely to contribute to ALS pathophysiology. Several in vivo models of TDP-43 
dysfunction, including both knockout models and models overexpressing the wild-type 
and mutant forms of the protein, have recently been generated in Mouse, Rat, Drosophila 
melanogaster, Zebrafish and Caenorhabditis elegans80,81. 
A note of caution relating to genetic studies is that, although gene structures are often 
similar between species, intronic sequences show great variability. Given the key role of 
TDP-43 in binding to long intronic sequences, the intraspecies variability in introns may 
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2.4 DNA repair 
Impaired DNA repair was suggested to have a role in ALS pathophysiology since the 
identification of FUS mutations, although the exact role of DNA repair failure in ALS 
remains to be clarified84. Interestingly both FUS and TDP-43 have been shown to be 
recruited by DNA damage; in fact, Wang et al. (2013) demonstrated that FUS is important 
in the mediation of DNA repair and DNA damage response (DDR) in post-mortem 
neurons, thus explaining how FUS mutations can alter the response to DNA damage 
leading to pathogenesis of neurodegenerative diseases84. 
TDP-43, like FUS, plays a role in the prevention and repair of damages associated with 
DNA as well as damages associated with DNA loops, thus helping both DNA stabilization 
and damages related to its transcription. Specifically, TDP-43 is localized in foci before the 
damage of endogenous DNA and its presence increases even more following DNA 
damage, suggesting the existence of some shared functions for FUS and TDP-4385. 
Mutations in NEK1 and C21orf2, which both encode for proteins involved in DNA repair, 
can cause ALS86-88, although the biological pathways associated with their causal role 
needs further confirmation.  
 
2.5 Nucleocytoplasmic and endosomal transport 
Perturbation of nucleocytoplasmic transport has been identified as a central mechanism 
underlying ALS-FTD, particularly those cases caused by mutations in C9ORF72, but is also 
involved in other neurodegenerative diseases as well as normal aging. The observation 
that most cases of ALS are associated with mislocalization of TDP-43 was, in hindsight, the 
first clue that the pathomechanism of ALS might involve an abnormality in nuclear 
transport. The temporal relationship among mislocalization of TDP-43, nuclear transport 
defects, and neurotoxicity in ALS remains unclear. It is possible that a primary defect in 
nuclear transport causes mislocalization and subsequent aggregation of TDP-43. Another 
hypothesis is that accumulation of cytoplasmic aggregates of TDP-43 drive a secondary 
defect in nuclear transport. Despite the accumulation of experimental data indicating 
impairment of nucleocytoplasmic transport through the nuclear pore complex (NPC) in 
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is thus far limited to redistribution of NPC components in end-stage disease. In addition, 
the relative pathogenic contribution of nucleocytoplasmic transport deficiency, compared 
to impairments in other cellular processes, has not been fully evaluated. Moreover, the 
relative roles of toxic species causing damage to nucleocytoplasmic transport machinery, 
whether toxic RNA or toxic DPRs, remain unresolved. While challenging, we anticipate 
that these issues will be addressed soon in this rapidly moving field89.  
 
2.6 Neuroinflammation and Excitotoxicity 
Activated microglia and infiltrating lymphocytes indicate an inflammatory component in 
CNS pathology of ALS90. Proinflammatory mediators, including monocyte 
chemoattractant protein 1 and IL‑891, are present in the (cerebrospinal fluid) CSF of 
patients with ALS, and biochemical indices of immune-response activation are present in 
the blood92. Reduced counts of CD4+CD25+ regulatory T (TREG) cells and monocytes 
(CD14+ cells) are detected early in ALS, suggesting recruitment of these cells to the CNS 
early in the neurodegenerative process. TREG cells interact with CNS microglia, 
attenuating neuroinflammation by stimulating secretion of anti-inflammatory cytokines93. 
Consistent with this scenario, double transgenic mice, carrying mSOD1 and lacking CD4, 
develop a more aggressive ALS phenotype, which is reversible by bone marrow 
transplantation94. Neuroinflammation is closely linked to activation of the immune 
response. A recent study identified CD40L — a ligand expressed by T cells that activates 
the immune response when bound by CD40 on antigen-presenting cells — as a promising 
therapeutic target95.  Proinflammatory mediators, including monocyte chemoattractant 
protein 1 and IL‑891, are present in CSF of patients with ALS, and biochemical indices of 
immune-response activation are present in the blood92. Reduced counts of CD4+CD25+ 
regulatory T (TREG) cells and monocytes (CD14+ cells) are detected early in ALS, 
suggesting recruitment of these cells to CNS early in neurodegenerative process. 
Excitotoxicity is a particular neuroinflammation process that is due, at least in part, to the 
excessive activation of glutamate N-methyl-D-Aspartate receptors, which causes an 
increased calcium input through the ionic channel associated with the receptor, thus 
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pathways related with the onset of ALS. A body of evidence implicates excitotoxicity as a 
mechanism contributing to motor neuron injury in ALS, although clear evidence that it is a 
primary disease mechanism is lacking. In some patients with ALS, levels of CSF glutamate 
are elevated96, and the expression and activity of EAAT2 are reduced in pathologically 
affected areas of the CNS97-99, although whether if this is a cause or a consequence of 
neuronal loss is unclear100. Electrophysiological studies in humans have shown 
hyperexcitability of the motor system in presymptomatic101 or early stages102 of ALS. 
Evidence suggests that the calcium permeability of AMPA receptors in the spinal ventral 
horn may be dysregulated by abnormal editing of the GluR2 AMPA receptor subunit103. In 
addition, a recently identified ALS-linked gene encodes d‑amino acid oxidase (DAO). This 
enzyme is responsible for the oxidative deamination of d‑amino acids, one of which — d-
Serine — is an activator and co-agonist of N‑methyl‑d-Aspartate (NMDA) receptors104. 
Mutations in DAO could potentially contribute to excitotoxic motor neuron injury. 
Excitotoxicity in ALS pathology leads to many events, including altered 
electrophysiological properties and increased sensitivity of motor neurons to 
excitotoxicity105, altered AMPA receptor subunit expression, reduced expression and 
activity of EAAT2106, increased glutamate efflux from spinal cord nerve terminals107, a 
reduction in motor neuron inhibitory–excitatory synaptic ratio108, and loss of regulation 
by astrocytes of the expression of GluR2 by neighboring motor neurons109. Ameliorating 
excitotoxicity is the only strategy that has, so far, slowed disease progression in ALS. 
Riluzole, which has several effects, including inhibition of presynaptic glutamate 
release110, causes a modest increase in survival111. 
 
3. Structure and function of TDP-43 
3.1 TDP-43 genetics 
TDP-43 or TARDBP (TAR-DNA Binding Protein-43) is a 43 kDa ribonucleoprotein, originally 
identified as transcriptional repressor of the HIV-1 TAR-DNA. The gene coding for TDP-43 
protein, consisting of 414 amino acids, is located along the short arm of chromosome 1 
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with the heterogeneous ribonucleoprotein family a series of key protein domains 
essential for its activity: 
● A Nuclear Localization Signal (NLS) domain at the N-terminal; 
● Two domains "RRM1 and RRM2" (RNA-recognition motifs): recognition of DNA 
and RNA; 
● A Nuclear Exportation Signal (NES) within the RRM2 domain; 
● The "Glycine-rich region" located at the C-terminal end: Glycine-rich domain for 
interaction with other proteins and to promote the exon skipping of some pre-
mRNAs 112,113 (figure 4). 
 
 
Figure 4: Graphic representation of TDP-43 functional domains of the protein. TDP-43 have structural 





TDP-43 has a predominantly nuclear localization and, as FUS, is involved in the regulation 
of many biological processes. In fact, TDP-43 is a DNA/RNA binding protein that 
participates in transcription regulation by promoting binding DNA transcription factors, is 
involved in the alternative splicing process, in biogenesis and maturation of microRNAs, 
and in transport and localization of some pre-mRNAs115. Additionally, TDP-43 is 
particularly important in regulating axonal transport and cytoskeletal integrity. Mutants 
and aberrant protein forms are therefore associated with a wide range of cellular toxicity 
phenomena116. Since 2006, studies on the composition of protein aggregates in neuronal 
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43 protein is the major constituent of such inclusions23. As for FUS, more than 40 
mutations were identified in TARDBP gene, and TARDBP pathogenic variants prevalence 
is: 
● 1.6% in all individuals with ALS (fALS and sALS) 
● 3.4%, but ranges from 0% to 12% across studies117,118 in fALS; 
● 1.1% but ranges from 0% to 5% across studies in sALS119,120. 
Most mutations fall within exon 6, that codes for the rich glycine region at the C-terminal 
end of the protein, and are inherited as dominant autosomal traits (Table 2). 
 
Allelic Variant Genotype-Phenotype 
Correlations 
Notes Ref. 
GLY298SER Earlier age of onset (mean 
50.7 years) and the most 
rapid rate of progression of 
disease (mean 27 months) 




ALA315THR Llater age at onset (mean 
66 years) and much longer 
survival (mean 110 months) 




MET337VAL Intermediate in their 
average ages at onset and 
survival times 
Methionine at this position is invariant in 
human, orangutan, mouse, opossum, 
chicken, frog, and zebrafish 
47
 
GLY348CYS Intermediate in their 
average ages at onset and 
survival times 
This mutant, which introduce a cysteine to 
the C-terminal hnRNP interaction region, 
was predicted to increase the propensity for 
aggregation through the formation of 
intermolecular disulfide bridges 
109
 
ALA382THR Intermediate in their 
average ages at onset and 
survival times 
This mutant is very common in Sardinia due 
to a founder effect. It accounts for 80% of 
familial ALS and 9% of simplex cases 
111,112
 
ASP169GLY Increases the hydrophobic 
interactions in the RRM1 
core, thus enhancing the 
thermal stability of the 
RRM1 domain 
This mutant is more susceptible to 




LYS263GLU The stability of the protein 
complex is less than that of 
the wild-type protein, 
indicating a reduced affinity 
for long nucleic acids 
This mutant shown to increase thermal 
stability by up to 3 °C in the apo state, 
which was unexpected due to its location 




Table 2. Principal mutations of TDP-43 protein. TDP-43 has several pathological mutations, represented in 
small part in this table, mostly located in the domain rich in wiccans, although there are many discreetly 
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The pathological manifestation, in type 10 ALS patients, is characterized by a great 
heterogeneity in terms of age of onset, aggressiveness of the phenotype and geographical 
location. In fact, some pathological mutants are characteristic of delimited geographical 
areas: a clear example is represented by the mutant TDP-43 A382T (defined as the 
"Sardinian variant"), which accounts for approximately 30% of total ALS cases in 
Sardinia121,122.  
 
3.2 TDP-43 protein aggregation 
As described in paragraph 3.1, TDP-43 is present in the protein aggregates of almost all cases of 
ALS. Pathologic TDP-43 is hyperphosphorylated, ubiquitinated and undergoes an abnormal 
proteolytic process, from which a 25KDa carboxy terminal fragment is generated, resulting in 
function loss. Neo-formed fragments are transported from nucleus to cytoplasm of neuronal and 
glial cells, where they tend to aggregate and precipitate123. Immunoprecipitation and 
immunoblotting experiments demonstrated how the cytoplasmic inclusions are subjected to 
ubiquitination and phosphorylation processes. The ubiquitination of misfolded proteins that 
aggregate in the cytoplasm and nucleus of neuronal cells, seems to be one of the key phenomena 
involved in the pathogenesis of neurodegenerative diseases and proteinopathies: in fact this 
phenomenon is appreciable in the most advanced stages of the disease. The formation of 
cytoplasmic inclusion bodies, therefore, would appear to be due to the presence of aberrant 




3.3 TDP-43 as transcriptional modulator 
TDP-43 was originally identified as a transcriptional repressor that binds to TAR DNA of 
human immunodeficiency virus type 1 (HIV-1) 124. Consistent with its role in transcription, 
TDP-43 was found, in human brain and in cell culture systems, to associate with 
euchromatin and to bind the promoter of mouse acrv1 gene, coding for SP-10 protein, 
which is required for spermatogenesis, acting as transcriptional repressor125. Recent 
evidences indicate that TDP-43 acts as a repressor of Acrv1 gene in spermatocytes and 
post-translational modifications, most likely ubiquitination, induce conformational 
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illustrates TDP-43 activity as a transcriptional repressor in vivo came from a recent report 
that identified rat and human VPS4B gene (vacuolar protein sorting 4 homolog B) as a 
TDP-43 target in brain, via direct binding to a TG-rich region in the promoter127. Moreover 
TDP-43 is associated with proteins involved in transcription, including methyl CpG-binding 
protein 2 (MeCP2)128. Beside this role as transcriptional repressor, TDP-43 has been 
indicated also as transcriptional activator, by luciferase assay or mRNA level 
determination for Bim promoter129, NFB responsive elements130, p53 binding elements131 
and CHOP promoter132. 
  
3.4 TDP-43 as modulator of RNA metabolism  
Splicing process is strictly regulated and is essential for an appropriate gene expression. It 
is not surprising, therefore, that dysfunctional spliceosome is closely linked to 
neurodegeneration. For example, when TDP-43 is removed from mouse embryonic stem 
cells, multiple cryptic exon have been coupled. This phenomenon has also been observed 
in cells from human patients with ALS and FTD133. 
TDP-43 shows the ability to bind RNA in a very specific way through the presence of two 
RRM motifs within its sequence, preferably UG repeats and UG/GU-rich repeats 
interspersed by other nucleotides, and the acetylation of residues K145 and K192, located 
in these domains, leading to reduced binding activity134,135. These observations were 
subsequently confirmed by CLIP analyses136,137, and a high resolution TDP-43 nuclear 
magnetic resonance structure that binds one of these sequences has been recently 
solved85. It should also be considered that the presence of a potential binding site does 
not always mean that it will play a fundamental role in a particular process138. 
In C. elegans, as well as in cell culture, TDP-43 loss induces the accumulation of double-
stranded RNA (dsRNA) and the abnormal processing of ribosomal RNA. Since it remains to 
be clarified whether these changes in RNA metabolism play a role in ALS/FTD pathology, 
several research groups are currently examining the molecular mechanisms with which 
TDP-43 limits the dsRNA and are trying to determine whether the loss of FUS and MATR3 
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Another important aspect is represented by cytoplasmic redistribution associated with 
TDP-43 disease, in particular in response to the expression of C9orf72 hexanucleotide 
expansion and the associated production of non-aggregated polypeptides139. 
 
3.5 Transposable Elements and TDP-43 
The transposable elements (TEs) are highly abundant genetic elements that constitute a 
great part of the eukaryotic genomes. Retrotransposons, which are transposed via an 
RNA intermediate, account for about 40% of the human genome140,141. Although most TE 
copies do not work, a subset has retained the ability to mobilize and even the stationary 
copies can be expressed142. Due to their potential to copy and paste into new genomic 
positions, TEs represent a huge endogenous reservoir of genomic instability and cellular 
toxicity141. The impacts of these genetic parasites are usually stifled by strong cellular 
mechanisms involving small interfering RNAs acting through induced RNA (RISC) to inhibit 
expression of transposon143. Although most surveys naturally focus on germs, where new 
insertions are inheritable and favoured from the evolution of the transposon, somatic 
tissues also have an active effect transposon mute mechanism whose functional meaning 
is less understood. As found in literature, TEs are normally active in brain144-147, and LINE 
and SINE (which are non-LTR retrotransponants) are even more expressed. LTR elements, 
on the other hand, have been associated with several neurodegenerative agents 
disturbances 148-154. With regard to this, it was evaluated by Wang group155 if TDP-43 RNA 
targets include transposon derivatives transcripts. Several recent studies used deep 
sequences for RNA analysis targets that co-purify with immunoprecipitated mouse, rat or 
human TDP-43, and also for profiling gene expression in mouse after TDP-43 abatement 
or excess expression156-159. 
From data in literature, it can be stated that TDP-43 is generally destined to derive from 
TE transcripts, including many short interspersed nuclear elements (SINE), long 
interspersed nuclear elements (LINE) and long terminal repeat elements (LTR) classes as 
some DNA elements. Secondly, the association between TDP-43 and TE-derived RNA 
targets is reduced in patients with FTLD with respect to healthy subjects, consistent with 
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3.6 The role of TDP-43 in mitochondrial translation 
Several research paper reported that, in ALS patients, TDP-43 co-localizes with various 
neuronal organelles in both human spinal cord and frontal cortex tissue samples, 
oppositely to what physiologically happens in age-matched normal individuals. 
In fact, it was demonstrated that in control cases, both in spinal cord motor neurons and 
in cortical neurons, TDP-43 mainly localizes in nucleus, while both ALS motor neurons and 
FTD cortical neurons showed characteristically higher levels of cytoplasmic TDP-43 
accumulation.  
Notably, cytoplasmic TDP-43 co-localizes with mitochondrial markers in many ALS spinal 
cord motor neurons or FTD cortical neurons, but minimally overlaps with markers of 
Golgi, endoplasmic reticulum, lysosome, autophagosome, endosome or peroxisome. 
Despite its low abundance in cytoplasm, TDP-43 co-localizes with mitochondria in motor 
neurons and cortical neurons in human control samples. Consequent sub-mitochondrial 
fractionation analysis, detected that mitochondrial TDP-43 was exclusively present in the 
inner mitochondrial membrane but not in outer mitochondrial membrane, 
intermembrane-space or matrix. Also Immuno-electron microscopy analysis of isolated 
mitochondria and biopsied human cortex confirmed the principal localization of TDP-43 in 
inner mitochondrial membrane cristae.  
Further studies on TDP-43 localization, showed that disease-associated mutations, such 
as A382T, influenced its mitochondrial localization too. 
It remains to be clarified whether TDP-43 deficiency alone is sufficient to cause neuronal 
loss, or if, with an inactivated nuclear localization signal, it causes a significant co-
localization of this protein with mitochondria, indicating mitochondrial localization as an 
intrinsic property of cytoplasmic TDP-43160. 
Since mitochondrial dysfunction precedes TDP-43-induced neuronal death, and since 
mitochondria are involved in almost all types of cell death, including apoptosis and 
necrosis, it could be of great interest understanding whether mitochondrial dysfunction is 
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4 Epigenetics and neurodegeneration 
4.1 Epigenetic modifications 
Epigenetics is defined as the set of potentially inheritable changes in gene expression that 
do not involve modifications in the nucleotide sequence of DNA137,163. The complexity of 
our organism clearly points out the existence in the genome of something more than DNA 
sequence that is capable of determining the great intra-inter-individual variability. The 
latter is also based on epigenetic modifications, which are responsible for the 
maintenance of chromatin stability and which are implicated in a wide range of 
neurodegenerative disorders164. To date, many molecular complexes are known to be 
responsible for chromatin remodelling, DNA-dependent enzymatic modification and DNA-
related histone proteins, as well as substitution of the same histones. Epigenetics is, thus, 
the configuration by which regulation of transcription and, hence, gene expression within 
our cells is realized and, in particular, it explains how genome written modifications are 
read, interpreted and removed, thus contributing to the stability and plasticity of nerve 




Figure 5: Waddington's vision of an epigenetic landscape. This image shows that DNA provides the stable 
base on which our individual details are written in the form of chemical marks. Most likely, the timing, 
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be in impacting such things as development and disease. Much remains to be elucidated, but the 
demonstration that external factors can alter the epigenome suggests that we can manipulate it, hopefully 
for good rather than evil. 
 
Chromatin can be defined as a plastic substrate capable of responding to rapid,short-term 
and long-term changes within cells. Modulation and regulation of gene expression, at 
chromatin level, involve different epigenetic mechanisms, which can remodel or modify 
chromatin template164-166. Chromatin remodelling activities are ATP-dependent and 
increase DNA-binding proteins accessibility to genome by altering DNA–histone 
interaction non-covalently. Chromatin modifying activities are carried out by introducing 
covalent modifications on histone tails, histone core proteins or by DNA methylation. 
Histone modification complexes make post-translational changes of covalent nature at 
the N-terminal end of histone proteins, such as acetylation, methylation, 
phosphorylation, ubiquitation, sumoylation, glycosylation and ribosylation. These post-
translational modifications, as well as the introduction of histone variants, co-operate in 
altering chromatin fiber167,168, changing the degree of chromatinic compaction, which 
closely correlates to transcriptionally active or inactive state169. The histone DNA-code 
interactions control the activation/repression of gene transcription; therefore, in case of 
transcriptional activation, compact and inaccessible DNA is made available to DNA 
binding proteins by chromatin modification170. For example, high levels of histones H3 
and H4 acetylation and H3 methylation on lysine 4 (H3K4me) are generally found in 
promoter regions of transcriptionally active genes, while high levels of H3 methylation on 
lysine 27 (H3K27me) correlates with polycomb-mediated protein transcriptional 
repression171. 
Of course, chromatin organization is designed to ensure that writing, reading and 
preservation of gene information is carried out within a well-defined spatial and temporal 
sequence, both during cell differentiation and during various stages of development164. It 
has long been suggested that histone modification patterns act as "recognition codes" for 
the recruitment of chromatin remodelling complexes and there are several experimental 
evidences that support the existence of the so-called histone code168,172. Histones N-







 Simona Sanna: “Epigenetics and neurodegeneration: physiological relevance of TDP-43/HDAC1 interaction”. 
Ph.D. Course in Life Sciences and Biotechnologies – University of Sassari. 
 
  
characterized protein domains, such as bromodomain, found in many chromatin-
associated proteins173,174. In addition, methylated lysine 9 of H3 is a specific recognition 
site for chromodomain, a domain typically involved in the formation of heterochromatin 
and in gene silencing; however, such residue may also be acetylated, and this 
modification is mutually exclusive with methylation175. In addition, H3 acetylation on 
lysine 14 from GCN5 HAT complex, is preceded by phosphorylation of serine 10 on the 
same tail; this suggests the existence of a regulatory cascade that controls the pathway, 
thanks to complexes capable of recognizing specific amino acid residues on the N-
terminal codons171. 
 
4.2 Acetylation and deacetylation 
Lysine acetylation and deacetylation in N-terminal histone tail, play a prominent role in 
regulating neuronal plasticity and transcriptional regulation164,176. The ability to influence 
neuronal vitality by modulating levels and activity of enzymes regulating nuclear 
homeostasis, such as HATs (Histone acetyl transferase) and HDACs (Histone deacetylase), 
has been demonstrated. It is now clear that the pattern of acetylation is strongly 
damaged in case of degeneration of nerve cells. Not unexpectedly one of the major 
causes of dysfunction and toxicity in cells is the imbalance in the presence of HATs and 
HDACs177. Acetyltransferases and deacetylases, combined with large multiproteinic 
complexes, catalyse opposite reactions on protein substrates, including core histones and 
transcription factors; in addition to regulation of transcriptional machinery, HAT-HDAC 
system is also involved in the modulation of replication, in DNA repair and in site-specific 
recombination177. Acetyltransferases and deacetylases, combined with large 
multiproteinic complexes, catalyse opposite reactions on protein substrates including 
core histones and transcription factors; in addition to regulation of transcriptional 
machinery, the HAT-HDAC system is also involved in the modulation of replication, and of 
DNA repair and site-specific recombination177. 
 
4.2.1 HATs 
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addition of acetyl groups derived from the Acetil-CoA. In particular, acetyl-transferase 
histones act on nucleosomal N-terminal tails and, in spite of the name, are also able to 
acetylate transcription factors such as p53, E2F and GATA1177. Acetylation of lysines 
neutralizes the positive charge of their ε-amine groups, thus reducing the affinity of these 
basic proteins to the acid DNA, altering histone core arrangement and relaxation of 
chromatin structure.  
All core histones are subjected to acetylation, but the ones occurring on histones H3 and 
H4 are more characteristic; the main targets of HATs are lysine 9 and 14 on H3 and lysine 
5, 8, 12 and 16 on H4-histone178. Acetylated lysine represent a surface on which many 
proteins with specific domains, such as bromodomain, can bind. Thus, chromatin is made 
more accessible to transcription factors. Acetylation of histones is consequently 
associated with transcriptional activation; on the contrary deacetylation closely correlates 
with gene silencing179. 
 
4.2.2 HDACs: functions, location and classification 
Histone deacetylation is related with the removal of acetyl groups from amino acid 
residues of N-terminal histone tails, leading to an increase in chromatin packaging, 
compatible with gene silencing. 
HDACs play a direct role in regulating transcription by deacetylation and regulation of TFs, 
or by interaction with transcriptional co-repressors. In Homo sapiens, 18 different HDACs 
have been identified, and have been divided into four categories based on their homology 
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Figure 6. Table representing Class I, II and IV HDACs. Class I (HDAC1, 2, 3 and 8), class IIa (HDAC4, 5, 7 and 





Cellular localization, as well as site-specific expression, differs between various 
deacetylases. In order to carry out their biological activity, HDACs have to move to 
nucleus, where most of the target substrates are located.  
Nuclear localization is guaranteed by the presence of a Nuclear Location Signal (NLS). 
Some HDACs are only nuclear, while others may be cytosolic, depending on the regulatory 
domains present. In particular, Class I HDACs, and a group of HDACs of class II (IIa), are 
the most expressed in cerebral areas associated with learning and memory183. 
Class I, II and IV HDACs have zinc-dependent active sites, while sirtuins require NAD+ 
(nicotinamide adenin dinucleotide) cofactor to function. However, interaction between 
different classes of HDACs is necessary for their biological activity. All HDACs have a 
catalytic domain consisting in about 390 amino acids with a highly conserved amino acid 
sequence. The active site consists in a slightly curled tubular pocket with a wide 
bottom184. The removal of acetyl group occurs through a charge system, consisting in two 
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the histidines and separated by 6 amino acids, and a tyrosine residue, located 123 amino 
acids downstream of aspartate. A fundamental component of this system is zinc ion, 
retained by its binding site at the bottom of the pocket, although other cofactors are 
required for the activity of HDACs. The conserved tyrosine catalytic residue is substituted 
by a histidine in Class IIa HDACs. This substitution greatly reduces catalytic activity185. 
 
4.2.2.1 Class I HDACs 
Deacetylases belonging to this class are expressed ubiquitously with a predominantly 
nuclear site. They show homology with the transduced yeast regulator RPD3 (Reduced 
Potassium Dependency 3) and are represented by HDACs 1, 2, 3 and 8186. These are 
largely expressed in brain, except for muscular-specific HDAC8, where they interact with 
key proteins that form part of large multi-unit complexes. 
HDAC1 and 2, respectively constituted by 482 and 488 amino acids, exhibit high structural 
and functional similarity with a sequence homology equal to 82%, and participate in the 
formation of large transcriptional repression complexes consisting of SIN3A, NuRD and Co 
-REST187, thus inactivating the expression of neuronal genes in non-nervous tissues188. 
In particular, such complexes act on multiple aspects, such as cell cycle regulation, 
maintenance of pluripotency of stem cells and cell differentiation189. HDAC1 and HDAC2 
are located in nucleus by acting not only on histones, but also on different substrates, 
including MyoD, E2F, p53 transcription factors and retinoblastoma protein. The two 
deacetylases carry out their biological activity only when incorporated into a multiproteic 
complex, which is, in fact, composed of proteins necessary for modulation of their 
deacetylase activity, DNA binding, and recruitment of HDACs on promoter regions. In 
addition, their activity, as well as the formation of repression complexes, is modulated by 
phosphorylation. Precisely, both deacetylases are phosphorylated by casein kinase 2 
(CK2) and, in addition, HDAC1 represents the target of other kinases such as PKA (cAMP-
dependent protein kinase A) and cGMP-dependent G protein kinase177. In resting cells 
HDAC1 and 2 are phosphorylated at low levels; when hyperphosphorylation occurs, there 
is a significant increase in deacetylase activity. Analysis of HDAC1 reveals two crucial sites 
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When these residues are mutated, the formation of protein complexes is hindered and 
HDAC1 biological activity is reduced190,191. 
In ALS context, HDCA1 has been described as the interaction partner of FUS during DNA 
repair; in addition, ALS-causing FUS mutant displays a reduced binding activity84. 
 
4.2.2.2 Class II HDACs 
Class II HDACs are homologous to yeast histone deacetylase 1 (HDA1), and represent a 
class that is further subdivided in two subclasses: 
• Class IIa HDACs, represented by HDACs 4, 5, 7 and 9; 
• Class IIb HDACs, represented by HDAC 6 and 10. 
The former have, in addition to deacetylase domain, an extended N-terminal regulatory 
domain that regulates nucleotide-cytoplasmic shuttling and DNA-specific binding, while 
the latter have distinct C-terminal domains192. They both show cellular and tissue-specific 
distribution, with a narrower expression pattern than class I HDACs, suggesting their 
possible involvement in cell differentiation and development193, but they are expressed 
abundantly in brain194; in particular, almost all move from nucleus to cytoplasm because 
of the presence of nuclear signal, while cytosolic retention depends on phosphorylation 
and interactions with proteins 14-3-3195. 
HDAC6, in particular, is expressed mainly in cytosol where it acts as an important 
constituent of cytoskeleton deacetylase, the α-tubulin196,197, but other substrates have 
been identified, such as TDP-43198. HDAC6 is the only enzyme with two deacetylase active 
domains organized in tandem and one zinc fingers (HDAC6-USP3 and Brap2-related zinc 
finger motif) domain in the carboxyl terminus. This latter domain is a signal for 
ubiquitination, suggesting, therefore, that this enzyme is particularly prone to 
degradation199. Although it is localized predominately in cytoplasm where, by inducing α-
tubulin deacetylation, regulates cell motility and microtubule-dependent cell adhesion197, 
it was detected also at nuclear level in association with HDAC11. In addition, HDAC6 
presents an activity independent from deacetylase functions200; in fact, by tying the 
ubiquitin, it participates, for example, at the autophagy process regulation and activity of 
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4.2.2.3 Class III HDACs 
Commonly known as sirtuins, because of its homology with SIR2 regulator identified in 
yeast201, class III HDACs are represented by 7 different NAD+-dependent enzymes 
expressed in the mammalian brain. In particular, SIRT1, 2, 6 and 7 are localized both in 
nucleus and in cytosol, while SIRT3, 4 and 5 exhibit mitochondrial localization202,203. 
Sirtuins catalyse the deacetylation of other targets than histones: for example, SIRT1 acts 
on targets such as TAF68 (TBP-associated factor 68), p53 and p300; SIRT2 has the ability 
to deacetylate α-tubulin exactly as HDAC6204; SIRT3, 4 and 5 determine the global level of 
acetylation in mitochondria by regulating energy metabolism, but also lipid metabolism 
and apoptosis186. 
In particular, many studies highlight the role of sirtuins in the maintenance of genomic 
integrity; in fact deficiency of their deacetylase activity is compatible with alterations in 
gene silencing, increased genomic instability and susceptibility to DNA damage. For 
example, it has been noted that SIRT6-deficient cells, accumulate a large number of 
chromosomal anomalies. Recent studies have also shown that this sirtuin is capable of 
affecting telomeric regions in human cells. Another important sirtuin, SIRT1, deacetylates 
factors associated with DNA repair mechanisms and is recruited on the same sites as a 
result of oxidative stress. Although this recruitment seems to have a protective role in 
genomic instability, it is accompanied by a depression of previously silenced genes, 
suggesting its implication in epigenetic silencing and chromatin modeling205. All sirtuins, 
except SIR2 and 5, have higher levels of expression in foetal brain with respect to adult, 
suggesting the crucial role of these molecules in initial brain development202. 
 
4.2.2.4 Class IV HDAC 
The only representative of this class, HDAC11, has common traits with class I and II HDACs 
but its function and substrates are still unknown. It can be found mainly in nucleus and it 
is expressed during the development of central nervous system of mammals, including 
oligodendrocytes, and plays a key role in maturation of this cell type206. It is also possible 
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4.3 HDACs regulation and deregulation in ALS  
4.3.1 Zn-dependent HDACs in ALS 
The implication of Class I HDACs in the onset of ALS was first shown by Janssen and 
colleagues209, which showed that in affected patients there is an over-regulation of 
HDAC2 in the motor cortex and in the grey matter of the spinal cord209, especially in the 
nuclei of motor neurons. Additionally, HDACs, in particular HDAC6, are increasingly 
implicated in ALS disease.  A recent study reported that FUS and TDP-43 proteins, altered 
in many cases of ALS, interact with each other, forming a ribonucleoprotein complex that 
regulates the expression of HDAC6, by influencing the levels of its mRNA210. In addition, in 
nerve tissue of ALS patients, nucleus and cytoplasm of motor neurons present low levels 
of HDAC11 encoding mRNA209. In neurodegenerative context, HDAC6 plays a significant 
role in α-tubulin post-translational modification, which modifies the properties of 
cytoskeleton; HDACs strictly regulate the acetylation of a preserved lysine residue (K40) 
on α-tubulin protein, to regulate the movement of organelles within cells, mediated by 
motor proteins appearance211; this is especially important for those neurons who have to 
carry a large load for long distances. 
The increase in acetylation levels in α-tubulin, following inhibition of the above-
mentioned deacetylase activity, improves transport in primary neurons, thus preventing 
axonal degeneration212,213. Considering that reduction of acetylation levels in α-tubulin is 
a characteristic pathological marker, an approach based on the use of HDACs inhibitors 
for the treatment of neurodegenerative disorders with neurons with particularly long 
axons, has been attempted. In this respect, ALS is a significant example because axonal 
transport efficiency loss, in both upper and lower motorneurons, is significant in the 
onset of the disease214. A lot of experimental work on the role of α-tubulin acetylation in 
ALS was conducted in SOD1 G93A mice, where it has been observed that HDAC6 genetic 
ablation positively influences acetylated α-tubulin levels in the central and peripheral 
nervous system, and maintains integral axons. Moreover the potential for muscle activity 
and the number of neurons in ventral spinal cord horns are increased, suggesting that 
these events that are associated with increased cell survival215. 
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nerve cells; first, HDAC1 assumes neurotoxic and neuroprotective character as it interacts 
with HDAC3 or HDAC9216. In fact, the role of HDAC1 in regulating neuronal vitality is quite 
controversial, since some studies show that such deacetylase is able to protect neurons 
from death, while other studies demonstrate that HDAC1 induces neurodegeneration and 
axonal death217. It, therefore, has a dual role, behaving differently depending on its 
molecular partner. Precisely, neurotoxic effect induced by HDAC1 requires interaction 
with HDAC3, which is toxic to motor neurons. 
HDAC1 interaction with HDAC3 is quite strong both in vivo and in vitro, and HDAC3 
repression suppresses HDAC1-induced neurotoxicity and vice versa. HDAC1 also interacts 
with HDRP, the truncated form of HDAC9, which is underrated in case of neuronal death. 
HDRP-HDAC1 interaction protects neurons from death, because high levels of such 
protein inhibit HDAC1-HDAC3 interaction, thus preventing neurotoxic action of both 
deacetylases216. In this regard, it was assessed the possibility that HDRP protects neurons 
from degeneration by preventing such interaction through the seizure of HDAC1; 
according to this hypothesis, HDAC1-HDAC3 association is strongly reduced when HDRP is 
expressed and, since HDAC3 does not interact directly with HDRP, it may be that the 
reduction in toxicity is due to the binding of the HDAC1. Overall, abovementioned 
considerations suggests that HDAC1 behaves as a kind of molecular switch between death 
and neuronal survival, although it remains to be clarified in which cellular compartment 
occurs the interaction between HDAC1 and HDAC3. HDCA1 has a nuclear localization 
signal and HDAC3 moves from nucleus to cytoplasm within neuron216. Although this may 
suggest a nuclear interaction, some recent studies indicate that in degenerative neurons 
HDAC1 moves to cytoplasm, where its presence is implicated in axonal alteration and 
degeneration of the cell213. In fact, the exposure of neurons to toxic stimuli, such as 
glutamate, promotes the passage of HDAC1 to cytosolic level mediated by CRM-1 nuclear 
receptor, thus inducing an alteration in mitochondrial transport. Specifically, the 
interaction of HDAC1 with cytosolic motor proteins, hinders their interaction with cargo 
proteins, resulting in the onset of swelling that appear as a succession of sagging and 
narrowing along the axon210. Neurofilaments, which represent the only axonal 
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phosphorylated in physiological conditions; phosphorylation levels correlate with the 
rapidity of axonal transport, probably affecting neurofilament-motor protein binding218. 
Conversely, hypoacetylated neurofilaments are more sensitive to calcium-activated 
calcium proteases, such as calpains and caspases, and exhibit greater tendency to 
aggregation219. Some studies show that high glutamate concentrations in neuronal 
cultures weaken transport along neurofilaments, and induce build-up of cytoskeletal and 
organoleptic proteins in localized granules and local destruction of axonal transport220. 
However, it remains to be clarified whether the input of calcium ions and the activity of 
HDAC1 are independent mechanisms associated with early or late axonal damage stages, 
although it has been observed that the passage of HDAC1 into the cytosol requires Ca2+. 
Such translocation is permitted by the presence of a leucine-rich region, similar to nuclear 
signal (NES), which interacts with CRM-1 receptor. The effects of the transport of HDAC1 
into cytosol on the instability of axon are not due to a loss of its nuclear function but it is 
due to the acquisition of a cytosolic function. In fact, the toxic effect of cytosolic HDAC1 is 
due to its ability to bind proteins such as KIF2A, KIF5 and α-tubulin, preventing them from 
forming complexes with cargo proteins such as dynamite210. 
 
4.3.2 NAD+-dependent HDACs in ALS 
Unlike other deacetylases, the activity of sirtuins in the SNC appears neuroprotective. 
Protective agents such as polyphenols, in particular resveratrol, selectively activate both 
SIRT1 and SIRT2221. Cortical neurons of SOD1 G93A transgenic mouse treated with 
resveratrol, appear to survive longer because of the activation of SIRT1 that deacetylates 
the FoxO3a transcription factor, which is responsible for determining cellular destiny in 
stress situations222. SIRT1 then leads to its activation or inhibition, depending on 
deacetylase residue or depending on cellular location of FoxO3a223.  
Moreover SIRT1 and SIRT2 have been described to be misregulated in G93A-SOD1 and 
G86R-SOD1 mice. SIRT1 decreases in the spinal cord, but increases in muscle during the 
progression of the disease, while SIRT2 mRNA expression increases in spinal cord, even if 
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4.4 Role of HDACs in Neuronal Development and Growth 
It has long been known that HDACs are implicated in neurogenesis, a process that 
involves the formation of new neurons from non-mature cellular precursors. In particular, 
cell-specific expression of HDACs in central nervous system, suggests the specific roles in 
neuronal development; for example missing HDAC1-HDAC2 precursors doesn’t allow cells 
to differentiate into mature neurons and are therefore confronted with death226. 
Although HDACs are enzymes generally associated with transcriptional repression, HDAC1 
is also able to act as a positive transcript regulator during the neuronal development of 
the central nervous system of Zebrafish, since genes regulated by such deacetylase 
encode for transcription factors implicated in the promotion of neuronal specification226. 
HDAC3 is involved in the control of gene expression during neuronal development and 
maintenance of neuronal stem status, while HDAC5, as well as other molecules belonging 
to class II HDACs, is involved in differentiation of neurons192. In addition, histone 
deacetylase is involved in neurite formation as well as dendritic and axonal growth; these 
processes are dependent on cytoskeletal rearrangements227 and largely dependent on 
microtubules and actin filaments deacetylation228. HDAC6 controls microtubular dynamics 
to optimize neurite formation through septin, which represents a scaffold that allows 
HDAC6 to perform its activity efficiently229. 
HDACs also play a key role in development of dendrites, as loss of HDAC6 in cerebellar 
and hippocampal neurons reduces both length and dendritic branching, thus highlighting 
its dendritogenic activity. However, this function is independent on its deacetylase 
activity and requires direct interaction with Cdc20-APC complex230. HDAC1, HDAC2 and 
HDAC9 are also implicated in dendritic growth.  
Another role is the regeneration of axons damaged by reorganization of HDACs mediated 
microtubules231,232; the influence of calcium ion induced by active HDAC5 cell damage, 
which reduces tubulin acetylation levels, results in reduced microtubule stability. This is, 
in fact, necessary for the regeneration of axon233. Sirtuins are also implicated in neuronal 
development and in the protection of nerve cells; for example, during the neurite genesis, 
SIRT2 controls tubular acetylation, while SIRT1 plays a key role in stimulation of axonal 
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In general, gene expression is directly proportional to the level of acetic acid. This 
happens because acetylation pattern regulation is essential to maintain gene 
homeostasis. Thus, until acetylation and deacetylation events mediated by HATs and 
HDACs occur synchronously, modulation of gene expression is performed correctly. 
However, transcriptional dysfunction represents a mechanism involved in the death of 
motor neurons235. There are many evidences that deregulation of transcription may be or 
may be not the cause of many neurodegenerative disorders such as ALS, Parkinson's 
Disease, and Alzheimer's. 
Although causal mechanisms and causal relationships are still under study, it has been 
hypothesized that protein inclusions of mutated forms, such as SOD1 and TDP-43, that 
are formed in pathological neurons, can cause toxicity, since sealing surfaces that can 
seize components are essentials for transcriptional machinery. It has been shown that 
inhibition of deacetylase prevents protein aggregation236. In particular, inhibition of 
HDACs in motor neurons cultures protects cells from excitotoxicity, which is a mechanism 
involved in the pathogenesis of ALS237. There are different ways in which changes 
mediated by HDACs are involved in neurodegeneration; in some cases, 
neurodegenerative disorder is caused by a HDAC-dependent transcriptional decreasing of 
a certain protein with consequent loss of function, whereas in other cases mutations are 
identified due to extensive transcriptional deficits along the genome186. In addition, 
HDACs do not only act on histones but also on a wide variety of targets, thus playing a 
wider role in cellular biology. 
 
4.5 HDACs inhibitors 
On the basis of considerations made in previous paragraphs, it is evident that 
pharmacological inhibition of HDACs can be an interesting therapeutic opportunity for 
ALS. 
Various HDACs inhibitors (iHDAC), selective and non, synthetic and natural, used to stop 
proliferation in experimental neoplastic models222, are available. Four large classes of 
inhibitors used in several clinical trials have been identified, some of which have already 
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• Short chain fatty acids such as butyrate (NaB), phenylbutyrate (SPB) and valproic 
acid (VPA), 
• Hydroxy acids such as trichostatin A (TSA) obtained from the fermentation of 
Streptomyces and oxamflatin, 
• Ortho-aminoanilines, such as MS-275, 
• Cyclic tetrapeptides, mostly derived from bacteria and fungi, such as trapoxin and 
FK228. 
Most of them act as chelating agents against enzyme active site containing zinc, thus 
acting as competitive inhibitors and blocking the accessibility of acetyl lysates to the 
active site of HDAC. HDACs inhibitors have, in fact, a zinc atom with chelating activity into 
their active site, a linker region that accommodates the entry into the active site and a 
"hood" group, linked to the linker region via a small connection unit, to allow external 
surface interactions238. 
All inhibitors act by inhibiting reversible HDACs, with the exception of trapoxin and 
depudesine, which in fact bind the enzyme at the level of the epoxicone group covalently 
and irreversibly222. 
The non-specificity of such inhibitors is responsible for the contradictory effects found in 
different cell types, since inhibition of HDACs seems to be primarily protective in nerve 
cells and, in turn, deadly in cancer cells. From the beginning, most of the work on these 
small molecules was initially focused on apoptotic and anti-proliferative effects in tumor 
cell lines and it was, in fact, believed that the increase of histone acetylation following 
HDAC inhibition, activated the transcription of pro-apoptotic genes. In fact, it has been 
found that increased acetylation promotes also the expression of survival genes such as 
Bcl-2 and growth factors, thus providing protection to different cell types from neoplastic 
cells such as neurons177. 
Many studies, therefore, show neuroprotective effects induced by inhibitors of HDACs; as 
shown in Figure 7, treatment of neurons with such molecules results in histone 
hyperacetylation, which results in greater opening and accessibility of chromatinic 
conformation, resulting in recruitment of chromatinic remodeling complexes that bind 
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Figure 7. Effects of HDAC inhibitors: When disabled, HDACs can not mediate chromatin condensation. This 
promotes the transcriptional activation of protective genes. 
 
In the presence of inhibitors of HDACs, an increase in acetylation levels is observed for H3 
and H4 histones and other proteins such as p53193. 
HDACs inhibitors exhibit varying potency and selectivity, and it is possible to diversify 
selectivity by modifying the chelating region. Among non-selective inhibitors, TSA and 
Vorinostat are found to inhibit many zinc-dependent HDACs, including HDAC6, due to the 
ability to cross blood vessel barrier. Fatty acids such as NaB and SBP are able to inhibit 
most class I and II HDACs.  
A fairly known inhibitor, VPA, binds to the active site by inhibiting both class I and IIa 
HDACs, but does not exhibit activity against Class IIb HDACs217, although the susceptibility 
of class II HDACs to that inhibitor is five times lower than that of class I HDACs193. 
However, given the poor selectivity, recent attempts have been made to produce more 
selective inhibitors such as: 
● MS-275, a synthetic benzamide that preferably inhibits HDAC1; 
● romidepsin (FK228), a cyclic tetrapeptide that strongly inhibits HDAC1 and HDAC2; 
● tubacin, which exhibits high selectivity for HDAC6; 
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●  nicotinamide, precursor of NAD + and selective sirtuins inhibitor. 
 
Many of these compounds were tested in transgenic mouse models SOD1. For example, 
treatment with TSA induces a modest improvement in motor capacity and protection 
against motor neuron and axonal degeneration, muscular atrophy and denervation of 
neuromuscular junction239. VPA treatment, however, does not result in an increase in 
survival or motor performance, but still induces an improvement in the acetylation 
pattern in spinal cord by restoring intracellular levels of CREB factor in motor neuron of 
mice, with pathogenic mice resulting in prevention of neuronal death in case of 
excitotoxicity and hypoxia240. NaB is also capable of extending survival and motor 
capacity in the aforementioned pathological animal models, attributed both to over-
regulation of NF-B factor expression and other proteins involved in cell survival and stress 
response to reduced activation of caspase pathway241. The specific MS-275 inhibitor is 
particularly useful in presence of toxic stimuli leading to axonal damage; it, in fact, 
induces a calcium-dependent exporter of HDAC1, an enzyme that normally has nuclear 
localization. As already mentioned, its presence in cytosol interrupts the interaction of 
cargo and motor proteins resulting in loss of intracellular transport and cell death. MS-
275 then acts by inhibiting the activity of the HDAC1 enzyme210. 
Some inhibitors such as VPA, NaB and SPB have been tested in different clinical trials that 
have demonstrated the ability of these molecules to induce an increase in histone 
acetylation. 
However, there are several known undesirable effects associated with the intake of 
HDACs inhibitors; specifically, fatigue and weakness, gastrointestinal disorders, 
neurocortical manifestations, cardiac disorders, which result in non-specific 
electrocardiogram changes, and, in some studies, there is also a mild and transient 
thrombocytopenia. However, anaemic and neutropenic conditions are uncommon, and 
septic complications rarely occur242. In addition, the efficacy of HDACs inhibitors is closely 
dependent on their in vivo stability and, unfortunately, many of them do not have great 
stability and are therefore easily degraded by first-pass hepatic metabolism243. This is why 







 Simona Sanna: “Epigenetics and neurodegeneration: physiological relevance of TDP-43/HDAC1 interaction”. 
Ph.D. Course in Life Sciences and Biotechnologies – University of Sassari. 
 
  
restore and normalize the pattern of acetylation in motor neuronss of patients with ALS. 
 
5. Acetylated TDP-43 inclusions are linked to ALS 
Lysine acetylation has emerged as a major covalent modification controlling diverse 
cellular processes and has been implicated in Alzheimer’s disease (AD) and other 
neurodegenerative disorders244-248. For example, it has been demonstrated that 
acetylation of misfolded tau proteins marks mature neurofibrillary tangles (NFTs) in AD 
and related tauopathies, and represents a disease-specific marker of AD 
pathology241,243,244. In addition to tau, a global proteomics approach identified ~1,750 
proteins that are subjected to lysine acetylation, including a distinct subset of RNA-
binding proteins and associated factors.  
Given the importance of TDP-43 binding with RNA, one of the most studied aspects is 
whether post-translational modifications, such as acetylation, may somehow alter its 
normal function especially in all those molecular pathways that result then later in ALS. It 
has been extensively demonstrated that if such modifications fall on residues contained in 
RNA-binding domains (RRMs), they alter the normal binding to RNA, and also promote 
the accumulation of insoluble TDP-43 aggregates. Further confirmation of how 
acetylation may be a distinctive alteration in ALS typical neurodegeneration processes, 
was obtained by analysing lesions of the spinal cord of ALS patients, where TDP-43 was 
re-used to be largely acetylated, thus providing the presupposition for further study of 
this modification for therapeutic purposes, not only for ALS, but for many other 
proteinopathies associated with TDP-43198. 
It seems that acetylation modifies both function and localization of TDP-43. In fact, TDP-
43 in its WT form, normally located in the nucleus, seems to be subject to acetylation, 
although an higher cytoplasmic acetylation of TDP-43 have been detected, probably due 
to the different conformation of TDP-43 when it has cytoplasmic or nuclear localization, 
and because of different lysine accessibility. In addition, as TDP-43 primary cytoplasmic 
forms are observed in diseased brain and spinal cord, it is hypothesized that this increase 
in cytoplasmic cytotoxicity may be responsible, though only partially, for the formation of 
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In support of a pathological role, acetylation at K145 was sufficient to increase the 
pathogenicity of TDP-43 in cells, as demonstrated by both nuclear and cytoplasmic 
aggregation of TDP-43. Furthermore its C-terminus is widely phosphorylated and there is 
a consequent loss of its normal nuclear function. Based on all these scientific 
considerations, it can be hypothesized that aberrant acetylation of TDP-43 can act in a 
pathogenic way and that this can trigger the aggregation and loss of TDP-43 function. 
However, it remains to be investigated whether TDP-43 acetylation is limited to ALS or if 
this modification causes a wider range of TDP-43 proteopathies, thus expanding the 
clinical and therapeutic relevance of this phenomenon198. 
Acetylation also does not significantly alter steady-state TDP-43 protein levels in cell-
based system135.  
When the effect of acetylation on binding with target mRNAs is evaluated, particularly 
acetylation on K145 and K192 within the RRP domains of TDP-43, by means of mass 
spectrometry assay, obtained data suggest that even a single acetylation event is 
sufficient to compromise the binding and splicing functionality of RNA, thus 
demonstrating how modification on K145 causes a critical change in the TDP-43 function. 
Other data reported by Bhardwaj, show that non-specific K145 acetylation, induced in 
vitro using acetic anhydride, is more effective in the absence of RNA, suggesting that the 
RNA binding protects K145 from acetylation249. According to these experimental data, 
TDP-43 acetylation within the RRMs is sufficient to compromise normal RNA binding, thus 
forming a fast and efficient regulator switch to modulate TDP-43 association with 
downstream target RNAs198. 
In pathologic conditions, TDP-43 is abnormally phosphorylated on serine C terminal 
terminals (Ser-403/404 and Ser-409/410) by multiple kinases250-253, which is a highly 
specific marker of disease26,198,201. Although phospho-TDP-43 immunoreactivity is now 
considered to be an important biomarker in postomortem dignostics, it is not yet clear 
what the role of this post-translational modulation at TDP-43 level is. In fact, different 
research groups interpret phosphorylation as an incident that disadvantages aggregation 
instead of promoting it202,203, thus assuming the existence of additional signalling 
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Recent studies by Cohen on TDP-43 acetylation, point to a new therapeutic openness 
closely linked to translational post modifications that are often associated with proteins 
involved in ALS. In fact, it has been shown as one single acetylation-mimic (K145Q) 
modulating the TDP-43 RNA regulatory function, lead to a robust aggregation, when it is 
targeted at cytoplasm, triggering many of pathological distinctive signs associated with 
TDP-43 proteinopathy included hyperphosphorylation, mitochondrial perturbations and 
an inflammatory response. However, it is possible to improve chaperone function 
relieved the burden of TDP-43 aggregates through a HSF-1 transcriptional waterfall, as 
acting with an endogenous reconstruction program, it is able to engage and remove the 
TDP-43 in vivo inclusions251. 
Another important experimental test that best clarifies the key role of acetylation has 
been obtained from recent in vitro studies that have shown that loss of nucleic acid 
binding converts TDP-43 into unstable insoluble agglomerates247,248, implying physical 
association with nucleus that acids can act to stabilize the terminal C-terminal TDP-43 as a 
prion domain, bringing a more soluble functional protein that can thus act as a switch 
regulator to modify TDP-43 affinity for the target RNA. Indeed, treatment of cells with 
agents that increase oxidative stress and which promote loss of association with RNA led 
to TDP-43 acetylation and insoluble accumulation. 
It is probable that acetylation of K145 residue, located in the site that allows TDP-43 
DNA/RNA linkage, is facilitated, as this site is more accessible, thus allowing a more rapid 
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Figure 8 Acetylation and deacetylation cycle of TDP-43. TDP-43 which normally has a high affinity for nuclei 
when it is subjected to excessive stress oxidizing, for example by external factors or genetic factors, 
undergoing modifications such as crosslinking of cysteine disulfide11 and lysine acetylation , going to alter 
the affinity of the bond with RNA but above all, leading to a buildup of protein in the cytokine and nucleus. 
These agglomerates are easily linked by the HDAC6 / CHIP / Hsp70 complex which is capable of deacetating 
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MATERIALS AND METHODS 
 
Antibodies and reagents 
The following primary antibodies were used in this study: Myc monoclonal antibody 
(M4439, Sigma-Aldrich), β-actin antibody (A5441, Sigma-Aldrich), Flag (F3165, Sigma-
Aldrich), HDAC1 (10197-1-AP, Proteintech), TARDBP (190782-2-AP, Proteintech), 
Acetylated-Lysine antibody (9441, Cell Signaling), anti-rabbit peroxidase-conjugated 
secondary antibody (AP132P EMD Millipore and anti-mouse peroxidase-conjugated 
secondary antibody (AP124P EMD Millipore); anti-rabbit, anti-mouse Alexa 488 (A-11001, 
Life Technologies) or 647-conjugated secondary antibody (A-21244, Life Technologies). All 
antibodies were used at the dilution recommended by the manufacturer’s instructions.  
The following HDAC inhibitors were used in this study: Sodium phenil butyrate (SML0309, 
Sigma-Aldrich), Trichostatin A (T8552, Sigma-Aldrich), Sodium butyrate (B5887, Sigma-
Aldrich), Valproic acid sodium salt (P4543, Sigma-Aldrich).  
 
Mice tissue 
Mice tissues were dissected from BALB31c mice housed at the Istituto Zooprofilattico 
della Sardegna (Sassari, Italy). All animal procedures have been performed according to 
the European Guidelines for the use of animals in research (86/609/CEE) and the 
requirements of Italian laws (D.L. 116/92, Directive 2010/63/EU). The ethical procedure 
has been approved by the Animal welfare office, Department of Public Health and 
Veterinary, Nutrition and Food Safety, General Management of Animal Care and 
Veterinary Drugs of the Italian Ministry of Health (Application number 32/08 of 7 July 
2008; Approval number 744 of 9 January 2009). All the experiments were performed by 
authorized investigators. Dissected tissue were immediately freezed in liquid nitrongen 
and stored at -80°C. 
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Plasmids construction and oligonucleotides 
Sequence coding for human TDP-43 (NM_007375.3) or human HDAC1 (NM_004964.2) 
were cloned in different expression vectors (pCS2-MTK, pCMV-3xFlag or pShuttle2) and 
used for site directed mutagenesis (QuickChange site-directed mutagenesis kit, Agilent). 
Mutants were obtained by mutagenesis starting from hTDP43, using the Quickchange 
site-directed mutagenesis kit (Stratagene) and primers indicated in the following table: 
 
Mutation Oligonucleotides 
M337V 5’CAGTTGGGGTATGGTGGGCATGTTAGC 3’ 
A382T 5’AATTCTGGTGCAACAATTGGTTGGG3 3’ 
K145A-K192A 5’ GATCTTAAGACTGGTCATTCAGCGGGGTTTGGCTTTGTTCG 3’ 
K145Q-K192Q 5’ GCCTTTGAGAAGCAGACAAGTGTTTGTGGGGCGCTGTACAG 3’ 
K236E 5’ TCCAATGCCGAACCTGAGCACAATAGCAATAGA 3’ 
D169G 5’ TTCTCTCAGTAGGGGGTGTGAT 3’ 
ΔNterm 5’ GAATTCAAGGCCTCTCGAGCCATAGTGTTGGGTCTCCCATGG 3’ 
ΔRRM1 5’ CAGAAAACATCCGATTTAATAGTGCCTAATTCTAAGCAAAGC 3’ 
ΔRRM2  5’ GAGCCTTTGAGAAGCAGAAAACACAATAGCAATAGACAG 3’ 
ΔG-rich 5’ CAGTTAGAAAGAAGTGGAAGAGGAATGTAGCTCGAG 3’ 
ΔRRM1- ΔRRM2 5’ CAGAAAACATCCGATTTAATAGTGCCTAATTCTAAGCAAAGC 3’ 
 
Table3: Primer tablets used for mutagenesis from hTDP43. 
Site-directed mutagenesis was performed according to instruction manual (Agilent 
Technologies Inc, Stratagene#200518). PCR was performed using oligos indicated in table 
3 and PFU DNA Polymerase (Promega, M7741).  
PCR was performed as follows:  
95 °C for 5‟ 
95° C for 3‟  
54-56 °C for 30‟‟  
72°C (1‟ for Kb)  
72° C for 10‟  
Repeated for 18 cycles 
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PCR amplified DNA was DpnI digested (to disrupt non mutated DNA), and then 
transformed in competent DH5α cells. Positive clones were screened by sequencing. 
 
Adenoviral vectors 
All adenoviral vectors (pAdenoX-hTDP43WT/Q331K/M337V/A382T/ΔRRM1-2/K145A-
K192A/K145Q-K192Q and pAdenoX-hHDAC1) were generated using the Adeno-X 
Expression System 1 (Clontech). Their production was completed in two stages. First, 
generation of mammalian expression cassette was done by cloning the gene of interest 
into pShuttle2. Second, excision of expression cassette from pShuttle2 and its insertion 
into I-Ceu I and PI-Sce I sites of BD Adeno-X Viral DNA was accomplished. All constructions 
were verified by automated sequencing. 
 
Bacterial strain 
Escherichia coli DH5-α were used as competent cells. Bacterial cells were defective for 
restriction and had mutations in relA1 and recA1 genes, to improve the stability and 
quality of recombinant plasmids.  
 
Cell lines 
SH-SY5Y cell line: SH-SY5Y cells (CRL-2266, ATCC, Rockville, MD) were human cells derived 
from neuroblastoma cell line.  
Adeno-X 293 cell line: Adenovirus 5-transformed Human Embryonic Kidney 293 cell line 
(CRL 1573 HEK 293; ATCC, Rockville, MD,) was used to package and propagate the 
recombinant adenoviral- based vectors produced with the BD Adeno-X Expression 
System.  
 
Cell culture  
SH-SY5Y were cultured in Dulbecco MEM/F12 ground (Gibco BRL), Adeno-X 293 in 
Dulbecco MEM (Gibco BRL), in presence of 10% fetal calf serum free of tetracycline 
contamination (Tet-free FCS, Clontech), previously inactivated at 56 °C for 30’minutes. 
Medium contained 100 units/ml of penicillin G and 100 μg/ml of streptomycin (Gibco 
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BRL). Cells were grown in an incubator at 37 °C, in (with) a humidified atmosphere 
containing 5% CO2. Trypsin (0.5 g/ml, 68 mM EDTA) was added to split cells and then 
diluted in fresh medium. Transient expression of each vector (2,5 µg DNA/1 × 106 cells) 
was obtained with Lipofectamine Plus reagent (Invitrogen) according to manufacturer's 
instructions. After an incubation of 4 h with transfection reagents, the cells were cultured 
in normal growth medium for 24 or 48 h. Trasduction with adenoviral particle with a MOI 
of 5 pfu/cell was performedaccording to6). 
 
Standard techniques of molecular biology.  
All standard techniques of molecular biology were performed according to Molecular 
Cloning–A Laboratory Manual7.  
 
Coimmunoprecipitation 
Briefly, cultured cells were lysed with lysis buffer (120 mM NaCl, 50 mM Tris pH 7.5, 5 mM 
EDTA, 0.5% NP-40, and 1 mM freshly prepared PMSF), containing protease inhibitors 
(SIGMA P 8340). Cell lysates were immunoprecipitated, overnight at 4°C, with specific 
antibodies; immunocomplexes were then captured by incubating, for 16 hours at 4°C with 
continuous gentle shaking, with protein-A sepharose from Staphylococcus aureus (SIGMA 
P3391). Subsequently, immunocomplexes were analyzed by means of Western blotting, 
using specific antibodies. 
 
SDS PAGE and Western immunoblotting 
Protein content was determined using Bradford protein assay (27813 SIGMA). Equal 
amounts of protein extracts were resolved by standard SDS/PAGE. Samples were then 
electroblotted onto Protan nitrocellulose membranes (GE Healthcare Life Science). 
Afterwards, membranes were incubated in 3% low-fat milk, diluted in 1 X PBS-Tween 
0.05% solution with the indicated antibody for 16 h at 4°C. Anti-Rabbit IgG (whole 
molecule)- and Anti-Mouse IgG (whole molecule)-Peroxidase antibody (EMD Millipore) 
were used to reveal immunocomplexes by enhanced chemioluminescence (Thermo 
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Fischer). The apparent molecular weight of proteins was determined by calibrating the 
blots with prestained molecular weight markers (Bio-Rad Laboratories). 
 
2D electrophoresis analysis 
Two-dimensional electrophoresis was been used to separate of proteins according to 
their isoelectric point (1st dimension) and, orthogonally, to their molecular weight (2nd 
dimension). 
The samples were applied to 70 mm IPG strips (pH 4-7, Bio-Rad laboratories), by 
overnight rehydration loading at 20 ° C, and subsequently isoelectrofocused at 50 μA / 
IPG strip for 22 kVh at 20 ° C. 
After focusing, proteins were in-gel reduced by incubating IPG strips with 50 mM Tris 
buffer containing 6 M Urea, 30% glycerol v / v, 3% SDS w / v and 1% DTT w / v, followed 
by in- gel alkylation with the same solution containing 2.5% iodoacetamide w / v, in place 
of DTT, under continuous shaking for 15 minutes before the second dimension. IPG strips 
were then sealed with 0.5% low melting point agarose w / v, in SDS running buffer, at top 
of second dimension gels (8 cm x 7 cm x 0.1 cm). SDS-PAGE was performed using 15% T, 
3% C polyacrylamide gels at 50V for 15 minutes and subsequently at 150V for about 90 
minutes. Later gels were subjected to western blot analysis, as described above. 
 
Immunofluorescence 
Cells were grown in 35 mm plates, fixed with 4% paraformaldehyde in 1 × PBS and 
permeabilized with 0.2% Triton X-100 in 1 × PBS. After a blocking step for 1 h in 5% BSA, 
diluted in 1 × PBS–0.05% Tween-20, cells were incubated with the primary antibody 
mouse anti-Myc (Sigma-Aldrich), diluted 1∶10000 in blocking solution, overnight at 4°C, 
and then incubated with a secondary antibody Alexa Fluor®488 goat anti-mouse IgG (Life 
Technologies), diluted 1∶1000 in blocking solution, for 1 h at room temperature. Cells 
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Chromatin Immunoprecipitation (ChIP) 
SH-SY5Y cells (4 x 106) were plated 24 hours before transduction, and infected by using 
viruses encoding for TDP WT at a multiplicity of 30 pfu/cell. After 24 hours, cells were 
harvested and chromatin immunoprecipitation was performed using EZ-Magna ChIP™ 
(Millipore), according to the manufacturer’s protocol.  
Each immunoprecipitated (IP) reaction was performed using about 1x106 cells equivalents 
of chromatin. The antibodies used for immunoprecipitation were the following: TARDBP 
Polyclonal Antibody (Proteintech_10782-2-AP) and Normal Rabbit Ig (reagent supplied) as 
negative control. Purified chromatin was eluted and DNA fragments were used for qPCR. 
 
Luciferase activity assay 
The DDIT3 (DNA-damage-inducible transcript 3, gene-synonym CEBPZ, CHOP, GADD1538) 
promoter from -954 to +91 was cloned between the XhoI and HindIII sites in the pGLE-
Basic Vector. All constructions were verified by automated sequencing. SH-SY5Y cells 
were seeded in 24-well plates and cultured for 16 h. Cells were then transfected by wild-
type or mutant of TDP43, HDAC1 and luciferase constructs, in addition to a Renilla vector, 
used as an internal control for luciferase activity; transfected cells were further cultured 
for 48h. Luciferase assays were conducted using dual luciferase assay system (Promega). 
Each experiment was performed in triplicate. 
 
Splicing assays 
SH-SY5Y cells (8 x 105) were plated 24h before transduction and then infected by using 
viruses encoding for TDP WT or with A382T mutation and for HDAC1 at a multiplicity of 
30 pfu/cell (plaque-forming unit/cell). After 48 hours, cells were harvested and total RNA 
was collected using Trizol Reagent (Invitrogen). Reverse transcription was performed 
using M-MLV Reverse Transcriptase (Promega), according to the manufacturer’s protocol. 
PCR with DNA Polymerase (Promega) was carried out for 25 amplification cycles (95°C for 
30 seconds, 55°C for 30 seconds and 72°C for 30 seconds). To test the splicing pattern of 
endogenous gene POLDIP3/SKAR the following primers were used: forward (5′-
GCTTAATGCCAGACCGGGAGTTGGA-3′) and reverse (5′- 
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TCATCTTCATCCAGGTCATATAAATT-3′). To evaluate transduction efficiency and expression 
of exogenous TDP, both WT and mutant, and HADC1, PCR reaction was performed by 
using the following primers: TDP-forward (5’-AACAATCAAGGTAGTAATATGG-3’), TDP-
reverse (5’-TGTAACCATTATAAGCTGCAA-3’) and HDAC1-forward (5’-
AAATGCAGGCGATTCCTGA-3’), HDAC1-reverse (5’-TGTAACCATTATAAGCTGCAA-3’). All 
PCR products were analyzed on 1.5% agarose gels. 
Densitometric analyses for the quantification of agarose gels were performed using 
Quantity One software program (Bio Rad Laboratories). 
 
qPCR 
2µl aliquots of each sample was used in triplicate for qPCR analysis of the CHOP 
promoter. Thermal cycling was performed using a Rotor-Gene Q (Qiagen). SYBR Green 
(Invitrogen) was added at 1:10,000 dilution to each 20µl PCR reaction. qPCR was 
performed in triplicate for each input, control (IgG antibody) and immunoprecipitation 
sample (TDP antibody).  
DNA in immunoprecipitated samples was quantified and relatively expressed by using 
control IgG samples set as 1. 
Factor binding to the CHOP gene was determined to be significantly enriched using one-
way ANOVA.  
The primers used to perform the qPCR are the following: CHOP1-F (5’- 
GTGAAACGTAGTCTCGCTCTG -3’) and CHOP1-R (5’- CCAGCTAATGGGCACATAGG-3’), 
CHOP2-F (5’- CCCAGTGGATGGATACCAAC-3’) and CHOP2-R (5’- GTTTGGCAACCGGTGTCTG-
3’), CHOP3-F (5’- CAGACACCGGTTGCCAAAC-3’) and CHOP3-R (5’- 
GCCTTAGACTTAAGTCTCTGACC-3’), CHOP4-F (5’- CTCCAGGGTTCAAGCGATTCT-3’) and 
CHOP4-R (5’- AGCGGATCACTTGAGGTCAG-3’), CHOP5-F (5’- AACGGCGGGTAAAGCTAGG-
3’) and CHOP5-R (5’- GTGGGGGAGAGGAGAGAGG-3’), CHOP6-F (5’- 
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Silencing histone deacetylases1 (HDAC1) gene by RNA interference.  
SH-SY5Y cells (1 x 105) were seeded 24 hours before the first transfection with the small 
interfering RNA (siRNA) oligonucleotide specific for HDAC1 gene. Lipofectamine 3000 
reagent (Lipofectamine® 3000, Invitrogen by Life Technologies) was combined with 
Optimem medium (Promega) (reaction 1); meanwhile, in a different tube, 148 pmolof 
HDAC1 siRNA and 500 ng of TDP, WT or mutant, were mixed with Optimem (reaction 2). 
Both reactions were mixed and left for 5 minutes at room temperature. Afterwards, the 
mix was added to the cells and incubated at 37°C and 5% of CO2. After 48 hours the 
transfection procedure was repeated only for HDAC1 siRNA, and cells were incubated at 
37°C and 5% of CO2 for other 24 houres. After 72 hours a MTS assay was performed, and 
cells were finally washed 2 times with PBS; subsequently, cell lysates were subjected to 
western blot analysis with anti-HDAC1 antibodies to evaluate expression level. 
 
Design of targeting components and the use of the CRISPR Design Tool 
The web interface of CRISPR Design Tool (http://tools.genome-engineering.org) was used 
to develop gRNAs, listed belowe. 
 
gRNA1 HDAC1F caccgTGAGTCATGCGGATTCGGTG 
gRNA1 HDAC1R aaacCACCGAATCCGCATGACTCAc 
gRNA3 HDAC1F caccgGATACCAGAGATGGCTTTTT 
gRNA3 HDAC1R aaacAAAAAGCCATCTCTGGTATCc 
gRNA6 HDAC1F caccgCCCAATGAAGCCTCACCGAA 
gRNA6 HDAC1R aaacTTCGGTGAGGCTTCATTGGGc 
 
Table 4. The oligo table used for creating the CRISP/Cas9 constructs. 
 
Off-target activity was evaluated additionally with Blastn 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
The pSpCas9(BB)-2A-Puro (Addgene # 48139) that expresses the Streptococcus pyogenes 
Cas9 (including an NLS and a FLAG tag) from a CAG promoter, and has a U6 promoter 
driven gRNA was used as cloning backbone according to (ran et al., 2013 Nature Protocols 
8, 2281–2308). Briefly, phosphorylation and annealing was performed with the three 
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couple of oligos, mentioned above, harboring a BbsI overhang. Afterwards, BbsI 
(#FD1014, ThermoFisher) mediated digestion and T4 DNA ligase (#M0318L, NEB) directed 
ligation in the linearized pSpCas9(BB)-2A-Puro was performed. After the transformation, 
cloning has been verified with a control PCR with the primers in the table. Plasmids were 
purified and sequenced. After transfection of the indicated combinations of pSpCas9(BB)-
2A-Puro-gRNAs (Fig. 1B), positive cells were selected using puromycin (2 μg mL−1) for five 
days prior to clonal expansion. Empty pSpCas9(BB)-2A-Puro was used as negative control. 
 
HDAC inhibitors  
To inhibit HDAC1 activity, we used : Sodium phenil butyrate (SML0309, Sigma-Aldrich), 
Trichostatin A (T8552, Sigma-Aldrich), Sodium butyrate (B5887, Sigma-Aldrich), Valproic 
acid sodium salt(P4543, Sigma-Aldrich).  
Sodium Butyrate was weighted, solved in water at a stock concentration of 10 mM, and 
then diluted at the final concentration of 0,2 and 0,04 mM. Trichostatin A was solved in 
ethanol, at the stock concentration of 1 mg/ml, and then diluted at the final 
concentration of 10 and 25 nM. We plated target cells (SH-SY5Y or CRISP-Cas9 HDAC1 
clones) in culture plates desired 12–24 hours before infection. The next day, we removed 
the growth medium and infected target cells diluting viruses at a multiplicity of between 
5–30 pfu/cell in OPTIMEM (Thermo Fisher Scientific). We then incubated the cells in a 
humidified CO2 (5%) incubator at 37°C for 1 hour, to allow virus to infect the cells. Then, 
we added fresh complete growth medium and incubated in a humidified 5% CO2 at 37°C 
to allow the expression of the adenoviral construct. We analyzed gene expression at 
different time points, previously decided, and then we proceeded with further 
experimental manipulations. 
Viability of both control SH-SY5Y cells or SH-SY5Y cells infected with adenoviruses 
encoding for TDP-43-causative gene, was calculated after 72 hours, through an MTS 
assay. Cell viability was assessed by a colorimetric assay using 3(4,5-dimethylthiazol-2yl)-
5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium (MTS) assay (Cell Titer 96 
Aqueous One Solution Assay, Promega), according to manufacturer’s instructions. 
Absorbance at 490 nm was measured in a multilabel counter (Victor X5, PerkinElmer). 
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DNA Damage  
SH-SY5Y cells (1 x 105) were plated 24 hours before transduction, and infected by using 
viruses encoding for TDP WT, M337V, A382T, ΔRRm1-2, KK-AA and KK-QQ at a multiplicity 
of 40 pfu/cell . 
48 hours after infection, for UV irradiation, cells were treated with UV-C (254 nm) using a 
lowpressure mercury lamp, and the cells were either subjected to global (5 J/m2).  
After the microirradiation, cells were incubated for 4 hours at 37 °C, in a humidified 
atmosphere containing 5% CO2. All slides are processed successfully by assaying the 




The results are presented as means ± S.D. of n≥3 independent experiments. Statistical 
evaluation was conducted by one-way or two-way ANOVA and Bonferroni post test. Values 
significantly different from the relative control are indicated with an symbol: *p<0,05; 
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TDP-43 interacts with HDAC1 in vitro and in vivo, via RNA binding domains 
Preliminary experiments performed in our laboratory (Masala A., PhD thesis 2016) have 
demonstrated that, in transfected SH-SY5Y cells, TDP-43 can interacts with HDAC1, in a 
similar way as it has been demonstrated for FUS9. To extend this result to more 
physiological conditions, co-immunoprecipation from mice neuronal tissues, using an 
anti-TDP-43 antibody, was performed. As shown in Figure 9A, a strong and specific 
interaction was observed between TDP-43 and HDAC1 in different neuronal tissues, but 
especially in the spinal cord.  
In order to extend these results, we performed a battery of co-immunoprepitation 
experiments. HEK293 cells were transfected with HDAC1 fused with Flag-tag in 
association with WT or pathological mutant TDP-43 fused with Myc-tag and Myc-tagged 
FUS as positive control. We confirmed the interaction between FUS and HDAC1, and 
moreover TDP-43 interacts with HDAC1, independently from the pathogenic TDP-43 
variants M337V and A382T (Figure 9B-C).  
To characterize the domain(s) of TDP-43 responsible for the TDP-43/HDAC1 interaction, 
we generated a series of Myc-tagged TDP-43 fragments representing the various putative 
functional domains of the protein (N-terminal, RRM1, RRM2 and G-rich domain). Co-
immunoprecipitation experiments, performed on cell lysates from transfect HEK293 cells, 
demonstrate that TDP-43 interacts with HDAC1 via both RRM1 and RRM2 domains, and 
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Figure 9. TDP43 interacts with TDP43 in vivo and in vitro via RRM1 and RRM2 domains. 
A) Spinal cord, striatum cerebellum of BALB31c mice were used for co-immunoprecipitation experimets using 
α-TDP-43; B)HEK 293T cells were transiently transfected with Myc-tagged TDP43 WT or deletion mutant 
expression constructs (ΔRRM1, ΔRRM2, ΔG-rich, ΔRRM1/RRM2) and FLAG-taggedHDCA1; C) HEK 293T cells 
were transiently transfected with myc-tagged TDP-43 WT or mutant expression constructs (M337V or 
A382T) and FLAG-tagged HDCA1; D) Bar graph shows the relative binding of HDAC1 to mutantTDP-43, 
normalized to TDP-43 WT. The data were obtained from four independent experiments; *indicates p > 0.05 
and **indicates p > 0.01 versus WT binding, analyzed with one-way ANOVA. 
 
RMM1 and RRM2 domains have been shown to be crucial in TDP-43 physiopathology. 
They are necessary for regulation of alternative splicing and deletion of RRM-1 domain 
alters TDP-43 translocation in the nucleus5,10. Moreover the two major TDP-43 acetylation 
sites, K145 and K1925, and two of the three TDP-43 pathological mutants that are out of 
the Grich domain, ALS linked mutation D169G and FTLD-TDP linked mutation K263E11, are 
localized in this regions. Plasmids contructions coding for these mutants (D169G, K263E, 
RRM1-2, KK-AA, KK-QQ) were generated, transiently expressed in SH-SY5Y cells and 
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mutatedproteins is exclusively nuclear, with the exception of TDP-43 D169G which is also 
located partially in the cytoplasm. Moreover according to previous published results, 
Plasmids contructions coding for these mutants (D169G, K263E, RRM1-2, KK-AA, KK-QQ) 
were generated, transiently expressed in SH-SY5Y cells an 
 
 
Figure 10. Evaluation of TDP-43 WT subcellular localization and some mutants. (A) SH-SY5Y were 
transfected with the TDP-43 WT, D169G, K263E, RRM1-2, KK-AA,KK-QQ constructs and analyzed 48 hours 
later by immunofluorescence. The TDP-43 signal was revealed by primary anti-myc antibodies and anti-
mouse ALEXA 488 secondary. The slides were analyzed by Leica confocal microscope. 
 
Co-immunoprecipitation experiments were performed, using the indicated mutants as 
described in Figure 9 and only the acetylation mimic mutant (KK-QQ) displays a significant 
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Figure 11. Coimmunoprecipitation between TDP-43 mutants and HDAC1. A) HEK293T cells were transiently 
transfected with myc-tagged TDP-43 WT or mutant expression constructs (D169G, K263E, ΔRRM1-2, KK-AA 
or KK-QQ) and FLAG-tagged HDCA1; B) Bar graph shows the relative binding of HDAC1 to mutant TDP-43, 
normalized to TDP-43 WT. The data were obtained from four independent experiments; **indicates p > 0.01 
versus WT binding, analyzed with one-way ANOVA. 
 
HDCA1 modulates TDP-43 acetylation 
Acetylated-TDP-43 was been demonstrated to be an HDAC6 substrate5. In order to 
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gel-analysis of immunoprecipitated TDP-43. SH-SY5Y cells were transfected with TDP-43 
alone or in combination with HDAC1 and 48h after transfection, TDP-43 was 
immunoprecipitated, separated by isoelectro-focusing (pH range comprised between 3 
and 6) followed by SDS/PAGE. The level of TDP-43 acetylation was evaluated using anti-
acetyl Lysine antibody (Figure 12).  
The co-transfection with HDCA1, as well as the one with HDAC6, that it has been shown 
to remove acetyl group(s) from acetylated targets, shifts the isoelectric point (pI) of 
immunoprecipitated TDP-43. This effect is partially prevented by deletion of RRM1-RRM2 
domains, confirming, as previously demonstrated, that K145 and K192 are not the only 
acetylated residues on TDP-43 and demonstrating that the TDP-43 interaction domain 




Figure 12. 2-DE maps reporting TDP-43 acetylation level after immunoprecipitation. Representative 2-DE 
maps showing the change in TDP-43 acetylation status, revealed by using an anti-acetyl lysine antibody, 
after immunoprecipitation with anti-Myc from HEK293 transfected with TDP-43, HDAC1 or HDAC6. 
  
Adenoviral delivery of TDP-43 and HDAC1  
In order to study TDP-43 physiopathology, in relationship with HDAC1, we decided to use 
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expression vectors exploit the high nuclear transfer efficiency and the low pathogenicity 
of the virus to deliver genes to the host cell (Adeno-X Expression System, Clontech). The 
assembly of recombinant adenoviruses has been completed in few stages: first, the cDNA 
encoding for HDCA1, TDP-43 WT, pathological mutants M337V and A382T, mutants 
K145A-K192A (KK-AA), K192Q-K192Q (KK-QQ) or ΔRRM1-2 were cloned into pShuttle2 
plasmid DNA. Second, the expression cassette was excised from recombinant pShuttle2 
vector by digestion with I-Ceu I and PI-Sce I, ligated into pAdeno-X and selected. Third, the 
recombinant adenoviral constructs were cleaved by PacI to expose the inverted terminal 
repeats (ITR) and transfected into HEK-293 AdenoX cell lines. After 7–10 days, viruses 
were harvested and amplified by infecting packaging cells for three times to obtain high 
titer virus stocks. The final yields were evaluated performing an end-point dilution assay. 
To characterize TDP-43 adenoviral expression vectors, recombinant adenoviruses were 
used to transduce SH-SY5Y cells with a scalar multiplicity of infection (M.O.I.): 5-40 
pfu/cell. Forty-eight hours after transduction, cells were lysed and protein extracts 
analysed by Western Blot. As shown in Figure 5 all adenoviral preparations are able to 
produce a high level of expression of TDP-43 (Figure A and B) and HDAC1 (Figure C) in SH-
SY5Y cell lines. Interestingly only the pathological mutants, and at a less extend WT TDP-
43, induce reduction in cell vitality at low MOI. The decrease in cell viability observed with 
the other mutants and with HDAC1 can be observed only with a MOI of 40 pfu/cell and it 
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Figure 13. Effect of adenoviral delivery of WT or mutant TDP43 and HDAC1 on SH-SY5Y cell viability. A) 
MTS assay on SH-SY5Y cells transduced by TDP-43 WT, M337V, A382T, ΔRRM1-2, KK-AA and KK-QQ 
adenoviruses, at a final concentration of 5, 10, 20 and 40 PFU/cell, and analyzed 48 hours after 
transduction. Cell lysates were subjected to reducing SDS-PAGE and western blot. The anti-TDP-43 antibody 
was used to visualize TDP-43 expression level and β-actin serves as controls for equal loading of samples. B) 
MTS assay on SH-SY5Y cells transduced by HDAC1 adenoviruses, at a final concentration of 5, 10, 20 and 40 
PFU/cell and analyzed 48 hours after transduction. Cell lysates were subjected to reducing SDS-PAGE and 
western blot. The anti-HDAC1 antibody was used to visualize HDAC1 expression level and β-actin serves as 
controls for equal loading of samples. C) The HDAC1 was detected by anti-HDAC1 antigen and secondary 
anti-rabbit ALEXA 647 or anti-Flag antigen and secondary anti-mouse ALEXA 488. The slides were analyzed 
by Leica confocal microscope. The data were obtained from four independent experiments; ** indicates p > 
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HDAC1 is not delocalized in the cytoplasm upon TDP-43 expression 
HDAC1, like most HDCAs, is a nuclear enzyme that can be rilocalised in the cytosol in 
damaged brain axons with multiple sclerosis, exemplary demyelinating models and in 
cultured neurons exposed to glutamate and TNF-α. More recently, during development of 
the Xenopus brain, HDAC1 was observed in both neurons and mitochondria of developing 
neurons12. TDP-43 instead is predominantly nuclear, although in fibrillary conditions it 
may move to the cytoplasm, causing a loss of function that results in detrimental effects 
on RNA metabolism. In pathological conditions, where TDP-43 is varied 
(hyperphosphorylated, ubiquitined, acetylated) and prompted to generate C-terminal 
fragments in the brain and spinal cord of frontotemporal lobo degeneration with 
ubiquitinated inclusions13.  
We therefore decided to test in our experimental models the subcellular localization of 
HDAC1 in the presence of different TDP-43 mutants. As shown in Figure 14, TDP-43, 
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Figure 14. Immunofluorescence analysis of TDP43 WT and deletion mutants localization and HDAC1 in SH-
SY5Y cells: A) SH-SY5Y cells were transduced with TDP-43 WT, M337V or A382T, without or B) with HDAC1. 
The TDP-43 signal was revealed by primary anti-myc antibodies and anti-mouse ALEXA 488 secondary, 
HDAC1 was detected by anti-HDAC1 antigen and secondary anti-rabbit ALEXA 647. The slides were analyzed 
by Leica confocal microscope. 
 
Physiological relevance of TDP-43/HDCA1 interaction: HDCA1 modulates 
TDP-43 transcriptional activity  
TDP-43 have been originally described as transcription factor for TAR DNA of HIV114, but 
at present the only other target on DNA is the testis specific mouse acrv1 (SP10) 
promoter15. TDP-43 has been also shown to induce a transcriptional up regulation of 
C/EBP-homologous protein (CHOP) promoter and the genetic disruption of the CHOP 
gene markedly attenuated TDP-43-induced cell death16. Moreover, the TDP-43-induced 
up regulation of CHOP expression is mediated by both reduction of CHOP degradation 
and by up regulation of CHOP mRNA level. Thus, we decided to use CHOP promoter (from 
-954 to +91) to drive the expression of luciferase reporter and to test the ability of WT 
and TDP-43 pathological mutants of regulating this promoter.  
48h after transfection with the indicated plasmid (Figure 15), SH-SY5Y cells were assayed 
for luciferase activity in a multiplate reader using the Dual-GlowTM Luciferase Assay 
System (Promega, USA). Firefly luciferase activity was then normalized to the Renilla 
luciferase activity to control the transfection efficiency. Data were then normalized to 
luciferase activity in cells transfected with empty vector, which was given a value of 
100%. As show in Figure 15 TDP-43 can act as robust activator of CHOP promoter. 
Transcriptional activation on this promoter was reduced when pathological mutants 
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Figure 15. HDAC1 overpression interferes with transcriptional activity TDP 43 on CHOP: The graph shows 
the data obtained from the luciferase assay performed on SH-SY5Y transfected with TDP-43 WT and 
different mutations, with or without HDAC1, showing that the presence of HDCA1 determines a reduction in 
CHOP transcriptional activation due to WT or mutated TDP43 expression, while this effect is no longer visible 
in the presence of the deletion mutant ΔRRM1/2. The data were obtained from four independent 
experiments; **indicates p> 0.01 and *** p > 0.001 versus HDAC1 expression, and indicates § > 0.05 and 
*** , § § > 0.01 versus TDP-43 expression; analyzed with two-way ANOVA. 
Since HDAC1 is a key component of an intricate network of acetylated substrates involved 
in transcription, not surprising, its overexpression induces a reduction of TDP-43 induced 
luciferase activity. Most importantly, also TDP-43 acetylation itself seems to be relevant 
for CHOP transcriptional activity since overexpression of the acetylation mimicking variant 
(KK-QQ), but not the non-acetylable mutant (KK-AA) impairs luciferases activity 
independently from HDAC1 overexpression.  
These experimental evidence indicate a possible direct interaction between TDP-43 and 
CHOP promoter, which we confirm by ChIP approach. In a first attempt we tested the 
CHOP promoter activation in response to sodium arsenite, using as marker of 
transcriptional activation the dual modification of histone H3 phosphorylated at serine 10 
and acetylated at lysine 14 (H3-PS10/AcK14). As expected CHOP transcriptional activation 
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Figure 16. Setting the ChIP on SH-SY5Y:The Figure shows the result of the ChIP performed on SH-SY5Y cells 
treated with Sodium Arsenite (10µM) for 1, 3 or 6 hours to evaluate the activation of the CHOP promoter in 
response to the treatment using an activation marker transcriptional such as the double modification of 
Hydroxy H3 phosphorylated to serine 10 and lysine 14 acetylated (H3-PS10 / AcK14). 
 
We, thus decided to transduce SH-SY5Y cells with adenoviral particle coding for 5xMyc-
TDP-43 and After 24 hours chromatin was extracted and immunoprecipitated using anti-
TDP-43 or anti-IgG as a negative control. As shown in Figure 17, we have been able to 
demonstrate that TDP-43 binds directly to the CHOP promoter by first amplifying a larger 
portion by using the pair indicated in materials and methods such as CHOP3-R and 
CHOP3-F, thus generating an amplifier of about 600 pb, then switch to the primer pair 
CHOP6-R and CHOP6-F, for qPCR, which amplify the reduced portion of the putative 
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Figure 17. Identification of TDP43 binding sites on CHOP promoter. A) To test the TDP-43 binding, we 
designed 6 pairs of primers that amplify several portions of the putative TDP-43 binding region on the CHOP 
promoter. Among these, the primer pair, CHOP 3 (indicated in the materials and methods), was selected, 
thus obtaining the amplified green region indicated in the figure used. B) The image shows the result of the 
agarose gel electrophoresis, of the analyzed samples qPCR after chromatin immunoassay. C) Actual banding 
was evaluated with data obtained from the qPCR and collected in the graph. The data were obtained from 
four independent experiments; ** indicates p> 0.015 for the fold enrichment analyzed with one-way ANOVA. 
 
TDP-43 splicing activity on POLIDP3 mRNA is modulated by acetylation 
levels, but not by HDCA1 overexpression  
Since it has been demonstated that the acetylation-mimetic TDP-43 mutant shows a 
reduction in the RNA binding and splicing functionality on CFTR transcripts17, we have 
examined in depth if HDCA1 overexpression may alter the TDP-43 splicing activity. As a 
target of TDP-43, we decide to monitor the inclusion of exon 3 of the interrelated 
polymerase delta [POLDIP3] mRNA, that has been demonstrated to be excluded by 
depletion of TDP-4318,19. RT-PCR experiments performed on SH-SY5Y cells demonstrate 





 Simona Sanna: “Epigenetics and neurodegeneration: physiological relevance of TDP-43/HDAC1 interaction”. 
Ph.D. Course in Life Sciences and Biotechnologies – University of Sassari. 
 
  
pathological mutation A382T and the non-acetylable KK-AA, stimulates POLDIP3 exon 3 
exclusion (increase of variant 2), effect that is exacerbated by the lack of RRM1-2 
domains. Surprisingly both the acetylation mimic KK-QQ induce a comparable exon 3 
exclusion, favouring a scenario in which the TDP-43 overexpression is altering the splicing 
pattern independently from any acetylation status. HDCA1 overexpression do not alter 
this phenomena in all the experimental conditions, althought we observed a genereal 
downregulation of exon3 exclusion in presence of HDAC1. 
 
 
Figure 18. TDP-43 splicing activity on POLIDP3 mRNA: A) Splicing diagram following the over-expression of 
TDP-43. B) SH-SY5Y cells transfected with TDP-43 WT and different mutants, with or without HDAc1 (C) 
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TDP 43 and HDCA1, their role in responding to DNA damage 
FUS and TDP-43 have been shown to play a key role in the response to DNA damage, 
since the loss of function of one of these two proteins results in a faulty repair of DNA 
damage associated with stopping in transcription20. Based on these data, we assessed 
whether the presence of HDAC1 could interfere with this specific TDP43 activity. To 
determine whether TDP-43 together with HDAC1 is localized at the DNA damage foci, we 
induce double strand brecks using UV-C rays on SH-SY5Y previously transduced with TDP-
43 WT or bearing different mutations. Immunofluorescence analysis demonstrates that, 
in irradiated cells, TDP-43 and HDCA1 colocalized in small spots, where, perhaps jointly, 
are involved in repair of DNA damage.  
In addition, by cell count we quantified the localization of TDP-43 following treatment 
with UV-C. TDP-43 WT as well as the pathological mutants, relocalized in the cytoplasm 
(figure 19 B). Only the acetylation mimicking mutant is retaine in the nucleus at the same 
extend in both treated and untreated cells KK-QQ. 
These data are also supported by the evaluation of cell viability following treatment 
(Figure 19 D), in fact, only with pathogenic mutants M337V and A382T there is a slight 
survival due to the loss of function due to mutated TDP-43 subtraction , which 
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Figure 19. WT and mutant TDP-43 colocalize with HDCA1 at DNA damaged foci. A) and B) SH-SY5Y 
transduced cells with TDP-43 WT and mutants treated with UV-C and analysed for TDP-43 and HDAC1 
localization. The TDP-43 signal was revealed by primary anti-TDP-43 antibodies and anti-mouse ALEXA 488 
secondary, HDAC1 was detected by anti-HDAC1 antigen and secondary anti-rabbit ALEXA 647. The slides 
were analyzed by Leica confocal microscope. C) The graph summarizes the image analysis, which reveals 
how TDP-43 becomes more cytoplasmic after DNA damage caused by UV-C exposure. D) The graph shows 
that as a result of UV-C exposure, there is less cellular survival in the specimens expressing the mutant 
M337V and A382T points. The data were obtained from four independent experiments; ** indicates p> 0.01 
for the cell survival analyzed with one-way ANOVA. 
 
TDP-43 and HDAC1 have a synergistic effect in decreasing cell vitality  
As described in the previous paragraph, WT or pathological mutant TDP-43 
overexpression is neurotoxic, inducing a reduction in cell survival, according to what it has 
been described in many other cellular and animal systems21-23. We thus decided to 
evaluate the effect of HDAC1 expression level or activity perturbation on TDP-43 induced 
cell toxicity.  
Data obtained in our laboratory have shown that HDAC1 stable overexpression in SH-SY5Y 
cells has a detrimental effect on TDP-43 mutated cell damage (Masala A. PhD thesis 
2016). Then we decided to manipulate the expression or the activity of HDAC1 to study 
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In order to knockdown HDAC1 we decided to use CRISPR/Cas9 genome editing technique 
in SH-SY5Y cells. To generate stable cell lines in which the expression of HDAC1 was 
blocked, SH-SY5Y were transfected with a plasmid coding for the humanized Cas9 and 
different gRNA targeting the second exon of HDAC1 gene. After the selection by 
puromycin, single stable clones were isolated and analyzed for HDAC1 expression (Figure 
20A and B), leading to the identification of two clones in which HDAC1 protein expression 
was absent (Figure 20B). The two clones were then further analyzed by 
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Figure 20. CRISPR/Cas9 genome modification of HDAC1 gene in SH-SY5Y cells: A) Summary of monoclonal 
lines generated by CRISPR-Cas9; B) Stable CRISP-Cas9 HDAC1 clones were analyzed to evaluate HDAC1 
expression levels by SDS-PAGE and Western blot using an anti-HDAC1 and (D) The HDAC1 signal was 
revealed by primary anti-HDAC1 antibodies and anti-rabbit ALEXA 488 secondary, β-actin was detected by 
anti-β-actin antigen and secondary anti-mouse ALEXA 647. The slides were analyzed by Leica confocal 
microscope. 
 
The two HDAC1-KO lines isolated were used in cellular vitality test, after being transduced 




Figure 21. HDAC1-KO cell lines display reduction in cell toxicity induced by TDP-43: A) Cell viability test in 
cell line SH-SY5YHDAC1 gRNA3 and HDCA1 gRNA8 (obtained using CRISP-Cas9 technology) after 
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HDAC1 and anti-β-actin. The data were obtained from four independent experiments; ** indicates p > 0.01 
versus SH-SY5Y, analyzed with one-way ANOVA. 
 
To extend this result, using a commercial HDAC1-siRNA, we induced a reduction of HDAC1 
protein level of about 70% that resulted in a statistically significant decrease of TDP-43 
induced cell toxicity, compared to the random sequence control (Figure 22), further 
confirming the results obtained by genetic ablation of HDCA1.  
 
 
Figure 22. HDAC1 silencing whit CRISP/Cas9 reduces cell toxicity induced by mutant TDP43: A) Cell viability 
test in SH-SY5Y cell line after transduction by adenovirus coding for TDP43 WT, M337V, A382T containing 
the 5xMyc epitope and following treatment with siRNA or scrambled. Western blotting using anti-TDP43, 
anti-HDAC1 and anti-β-actin. ** indicates p > 0.01 and *** p > 0.001 versus untreated with HDAC1 siRNA, 
analyzed with one-way ANOVA. 
HDAC inhibition has been shown to be protective in wide range of pathological 
conditions24,25, including ALS. The HDACi sodium butyrate (NaB), 4-phenylbutyrate (SPB) 
and Trichostatin A (TSA), fatty acid derivatives that inhibit most class I and II HDACs, have 
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of NaB it has been demonstrated in other neurodegenerative diseases such as Alzheimer 
disease26,27, Parkinson’s28 and Huntington29 as well as with SPB treatment extends survival 
and motor performance in SOD1-G93A mice models and in, a phase 2 clinical trial, it has 
been demonstrated to be safe and well tolerated30,31; TSA induces a modest improvement 
in motor function and survival as well as protection against motor neuron death32(Figure 
15); VPA, currently used for treatment of epilepsy, even if it did not improve survival of 
SOD1-G86R mice, it did improve the acetylation status on the spinal cord33. Moreover 
butyrates and valproic acid are also known to readily cross the BBB34. We thus decided to 
test the effects of these four HDACis on TDP-43 induced cell toxicity. 
In a preliminary experiment, we evaluated the cellular toxicity of the different HDAC 
inhibitors, using different HDACi concentrations, in a dose-response test that evaluated 
cell viability, as is shown in the figure 23. 
Using this test, it was possible to identify which of the concentrations we used, were not 
toxic after 48h of treatment, and for each of these inhibitors we have chosen two 
different concentrations: 0.04mM and 0.2mM for NaB, 10nM and 25nM for TSA, 0.1mM 
and 0.5mM for SPB. 
Afterwards, SH-SY5Y cells were transduced whit recombinant adenovirus coding for WT 
or mutant TDP-43 (M337V, A382T, K145A-K192A or K145Q-K192Q) and increasing 
concentration of the class I HDAC inhibitor NaB (0,04/0,2mM, Figure 24), TSA (25/10nM, 
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Figure 23. HDAC inhibitors used to evaluate the effect on TDP-43 overexpression induced toxicity: 
A)Summary table with the characteristics of the HDCAi used. The table shows the concentrations required to 
inhibit 50% of the enzyme (IC50) and some of the clinical trials currently in progress. B) Dose-response 
curves, data arise from the analysis of values obtained from the cellular vitality assay after NaB, TSA, SPB 
treatment. 
Cell viability assays performed 48h after transduction with adenoviral particles coding for 
WT or mutant TDP43 demonstrate a dose dependent increase in survival, upon NaB and 
SPB and at less extend also for TSA treatment (Figure 24, 25, 26). VPA on the contrary 
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Figure 24. Effect of HDAC inhibitor Sodium butyrate on SH-SY5Y cell viability overexpressing TDP43 
pathological mutant forms: Cell viability test in SH-SY5Y cell line after transduction with adenovirus coding 
for TDP43 WT, M337V, A382T and for TDP43 KK-AA, KK-QQ containing the 5xMyc epitope and NaB 
concentration at indicated concentration. Western blotting using anti-TDP43 and anti-β- actin.** indicates p 
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Figure 25. Effect of HDAC inhibitor Trichostatin A on SH-SY5Y cells viability overexpressing TDP43 
pathological mutant forms: A) Cellular vitality assay in SH-SY5Y cell line after transduction with adenovirus 
coding for TDP43 WT, M337V, A382T and B) for TDP43 KK-AA, KK-QQ containing the 5xMyc epitope and TSA 
treatment at indicated concentration. Western blotting using anti-TDP43 and anti-β actin. ** indicates p > 
0.01 and ***p > 0,001 versus untreated whit TSA, analyzed with one-way ANOVA. 
 
 
Figure 26. Effect of HDAC inhibitor 4-phenylbutyrate on SH-SY5Y cell viability overexpressing TDP43 
pathological mutant forms: A) Cellular vitality assay in SH-SY5Y cell line after transduction with adenovirus 
coding for TDP43 WT, M337V, A382T and B) for TDP43 KK-AA, KK-QQ containing the 5xMyc epitope and SPB 
treatment at indicated concentration. Western blotting using anti-TDP43 and anti-β actin. ** indicates p > 
0.01 and ***p > 0,001 versus untreated whit SPB, analyzed with one-way ANOVA. 
 
When the KK-AA and the KK-QQ mutants were expressed, the three inhibitors display a 
mild effect on cell viability, that do not reach statistical significance. 
The positive effect of -HDAC inhibition on TDP-43-induced cell toxicity was also confirmed 
in immunofluorescence experiments (Figure 27). HDCAi treated cells display a diffuse 
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Figure 27. Immunofluorescence in SH-SY5Y expressing different TDP43 isoforms treated with NaB 0.2mM, 
TSA 25nM and SPB 0.5mM. The cells were labeled with an anti-Myc antibody and detected with a secondary 
conjugate to Alexa 488 anti-mouse fluorophore as a secondary antibody. The slides were analyzed by Leica 
confocal microscope. 
 
Expression of hTDP43 in fly eyes leads to progressive eye defects, that is 
reduced by HDAC1 silecing  
We have demonstrated in three different experimental paradigms (gemomic inactivation, 
siRNA and HDACi treatment) that in SH-SY5Y cells the inhibition or the decrease in HDAC1 
level reduce the toxicity induced by WT or mutant TDP43. To confirm our results using an 
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Molecular Biology and Pathology, CNR, Rome Italy), we decided to use Drosophila, a 
powerful genetic model widely used to study neurodegeneration including ALS. 
Expression of hTDP-43 in the Drosophila eye leads to a well described retinal 
degeneration, as in Figure 28B, where large apoptotic areas, identifiable in as black 
portions are visible. But when the flies were crossed with a line in which Rpd3, the only 
HDAC1 and HDAC2 ortholog in Drosophila, is inactivated by expression of an RNAi, we 
clearly observe a reduction in retinal degeneration, which exhibits a much more control-
like phenotype with reduced or absent apoptotic areas (Figure 28C). 
This data demostrate that the silencing of HDAC1 in Drosophila, as well in SH-SY5Y cells, is 
sufficient to reduce the toxic effect induced by the over-expression of TDP-43. 
 
Figure 28. Expression of hTDP43 in fly eyes leads to progressive eye defects, that is reduced by HDAC1 
silencing: A) Drosophila line WT, B) Fly line, overexpressing human TDP-43, has a phenotype with obvious 
degeneration of the eye with wide apoptotic areas; C) the intersection of the line overexpressing human 
TDP-43 and with a line in which HDAC1 is silenced, shows a reduction in TDP-43 dependent degeneration. 
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ALS is predominantly a sporadic disease and environmental triggers may be involved in 
the onset of this disease, probably through epigenetic modifications (including histone 
post-translational modifications, DNA methylation, and RNA editing) that can be acquired 
during life and can contribute to explain pathogenesis, onset and progression. A better 
understanding of the genetic-epigenetic interaction can be crucial to fully comprehend 
the molecular mechanisms underlying motoneuronal death and, due to the reversible 
nature of epigenetic modifications, can be a key point for the design of new and more 
effective treatment (therapies).  
In this respect, the present PhD Thesis adds a new piece to this complicated puzzle, 
demonstrating that TDP-43 can physically interact with deacetylase-1 histone (HDAC1) 
both in vivo and in vitro (figure 9) and, since acetylated TDP-43 would impair its RNA 
binding activity and enhance the formation of aggregates17, targeting TDP-43 acetylation 
can be beneficial. 
We demonstrated that the interaction between TDP-43 and HDAC1 involves both RMM1 
and RRM2 domains, independently from the pathological mutations falling in these 
domains (D169G and K263E) or in the G-rich (M337V and A382T) (figure 11). Interestingly, 
TDP-43 has been demonstrated to undergo to an acetylation cycle that regulates not only 
the nucleo-cytoplasm shuttling, but also its binding activity to RNA17. The major, but not 
the exclusive, sites of acetylation have been identified on lysine 145 and 192, both 
comprised in the RMM1-RMM2 domains17. In our experimental paradigm, the mutant 
mimicking acetylation (referred to as KK-QQ, in whick K145 and K192 have been mutate 
in Q) loses HDAC1 binding activity, that is normal in the non-acetylable mutant (KK-AA). 
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The presence of additional and not yet identified acetylation sites, was further 
demonstrated by immunoprecipitation assays followed by 2D analysis, in which we 
observed that, in a similar way to HDAC6, the presence of HDAC1 changes (modifies) TDP-
43 isoelectric point, and that when TDP-43 lacks the ΔRRM1 and ΔRRM2 domains it is 
partially acetylated (figure 12). 
The RRM1 and RMM2 domains have been highlighted to have a fundamental role 
regarding the tight and highly specific binding of TDP-43 to UG repeats in RNA, and 
deletion of RMM1 alters not only TDP-43 role in splicing regulation10,19, but also its 
dynamics in the nucleus10. In fact mutants lacking functional RRM-1 display a strong 
nuclear-matrix–scaffold association, implying a role for RRM domains in chromatin 
organization10. In this respect we investigated the biological consequences of TDP-
43/HDAC1 interaction on some of the nuclear TDP-43 functions by monitoring 
transcription, splicing and DNA damage recovery.  
 
TDP-43/HDAC1 interaction and transcription 
Considering both that HDAC1 is a key component of an intricate network of acetylated 
substrates involved in transcription and that TDP-43 was found in human brain and in cell 
culture systems to associate with euchromatin, we first evaluated the functional 
relevance of TDP-43/HDAC1 by transcriptional assays. Despite TDP-43 has originally been 
described as a transcription factor for TAR DNA of HIV114, few target genes have been 
identified up to now. TDP-43 acts as a transcriptional repressor on both testis specific 
mouse acrv1 (SP10) promoter15 and on VPS4B gene (vacuolar protein sorting 4 homolog 
B)35, but can also act as a transcriptional activator on C/EBP-homologous protein (CHOP) 
promoter16, although no direct interaction has been demonstrated so far. By ChIP analysis 
and luciferase assays we demonstrated that TDP-43 binds and stimulates CHOP promoter 
activity (Figure 15, 17). This effect can be a key point for cellular response to the stress 
generated by the overexpression of mutant TDP-43. In fact CHOP gene, initially identified 
as responsive gene induced by genotoxic stress such as UV irradiation, under chronic or 
irreversible ER stress conditions, is activated by unfolded protein response (UPR) system, 
and contributes to cell cycle arrest and apoptosis36,37. In Alzheimer disease animal 
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models, increase in CHOP protein was measured in presenilin-1 mutant knock-in mice38 
and β-Amyloid induces CHOP expression both in cells and animal brains, whereas 
treatment of cells with CHOP antisense RNA improved neuronal survival after exposure to 
β-amyloid39. A similar beneficial effect due to the reduction in CHOP expression by siRNA 
was observed also in 6-hydroxydopamine model of Parkinson diseases40. In ALS context, 
CHOP overexpression was observed in spinal cord tissues from patients with sporadic 
ALS41 and in experimental models characterized by overexpression of either related or 
causing gene such as SOD141, OPTN42, VAPB43, as well as after treatment with β-
methylamino-L-alanine (BMAA)44. Here we demonstrate for the first time, by ChIP 
analysis, that TDP-43 WT is a direct activator of CHOP (figure 17). The pathological 
mutants A382T and M337V retain this ability and concomitant overexpression of HDAC1 
contributes to CHOP transcriptional down regulation. This effect is partially due to the 
general effect of HDCA1 on transcription, but TDP43 acetylation has a prominent role 
since KK-QQ TDP43 mutant does not activate CHOP transcription, despite its nuclear 
localization (figure 15 and 17). 
 
TDP-43/HDAC1 interaction and splicing 
Among the different TDP-43 splicing targets, POLIDP3 pre-mRNA has been widely used as 
a reporter gene in animal and cellular models, including SH-SH5Y cells45,46. RNA binding 
ability of TDP-43 is necessary to include POLDIP3 exon 3 and this can be relevant for the 
disease, since an increment of POLDIP3 variant-2 mRNA, in which exon 3 is excluded, has 
been described in motor cortex, spinal cord and spinal motor neurons collected by laser 
capture microdissection from ALS patients19.  
In SH-SY5Y cells the expression of a pro-aggregative TDP-43 mutant favours the synthesis 
of the POLDIP3 β isoform over the main α isoform, mirroring a protein level that was 
observed at mRNA level47. In our experimental paradigm we observed that WT or A382T 
TDP-43 overexpression stimulates exon 3 exclusion (decrease in V1/V2 ratio) and the 
concomitant HDAC1 overexpression do not significantly reduce this effect. When KK-QQ 
mutant is expressed the V2 isoform increases and the presence of HDAC1 has no effects 
on V1/V2 ratio. The overexpression of deletion mutant ΔRRM1-2 also exhibits a similar 
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phenotype, with a V1/V2 ratio reduction that is even more evident. This last effect can be 
due to an unrelated TDP-43 interaction with the POLIDP3 RNA, since TDP43 lacks RNA 
interaction domains, or via recruitment of endogenous TDP-4348,49. Globally these data 
indicate that the concomitant overexpression of HDAC1 with the different TDP-43 
mutants analysed do not alter the splicing profile of POLDIP3 (figure 18). 
 
TDP-43/HDAC1 interaction and DNA Damage Recovery 
The role of severe DNA damage and endogenous DNA repair strategies in ALS initiation 
and progression are well defined. TDP-43 and FUS are localized at sites of transcription 
associated to DNA damage, given their colocalization with γH2AX and phosphorylated 
RPA in an increased percentage of UV-damaged cells20. Moreover, like TDP43, FUS can 
interact with HDCA1 and this interaction is crucial for successful DNA repair after laser 
micro-irradiation9. By measuring the effect of WT or mutant TDP-43 overexpression in a 
cell damage paradigm (UV-C treatment) we show, for the first time, that pathological 
mutants M337V and A382T, as well as the acetylation mimicking mutant KK-QQ, reduce 
cell recovery (figure 19) whilst with a different mechanisms. In fact, while TDP-43 
relocalizes in cytoplasm upon (after) UV-C insult, KK-QQ mutant is retained in the nucleus. 
Although these data are preliminary and more experimental evidences should be 
provided, they may suggest that TDP-43, like FUS, colocalizes with HDCA1 on UV-
damaged DNA and the presence of pathological mutations worsens cell survival. 
 
TDP-43/HDAC1: the reduction of HDCA1 level or activity rescues TDP-43 
induced cell toxicity 
We provided evidence that TDP-43/HDAC1 interaction can have a deep impact on TDP-43 
molecular function at different levels and experimental evidence obtained with the 
acetylation mimicking mutant KK-QQ clearly indicates that the modulation of TDP-43 
acetylation status can be considered a new pharmacological target. Using different and 
complementary strategies, spanning from genetic inactivation by CRISPR/Cas9 technology 
or siRNA, to chemical inhibition using three different HDAC pan-inhibitors, we 
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demonstrated in vitro, in SH-SY5Y cells, and in vivo, in Drosophila eye, that HDCA1 
decrease/ablation can mitigate TDP-43 toxicity (figure 21, 22, 24, 25, 26, 27, 28). These 
results, although counterintuitive, can be explained considering that moderate TDP-43 
overexpression in mice results in downregulation of endogenous TDP-43 and causes TDP-
43 aggregation, axonal degeneration, reactive gliosis, gait abnormalities and early 
lethality50,51. In this context HDCA1 decrease/ablation, or in general treatment with HDAC 
pan-inhibitors, can stabilize TDP-43 acetylation and consequently protects cells from 
damage associated to TDP-43 translocation in the cytoplasm that most likely is acquiring a 
new toxic function(s). In this respect we are currently evaluating if HDACi treatment can 
prevent CHOP promoter activation, explaining the positive effect on cell viability, 
according to the positive effect of CHOP reduction by siRNA on SOD1 G93A toxicity52. 
 
Conclusion 
The data presented in this PhD thesis clearly indicate that TDP-43 
acetylation/deaceteylation status, mediated also by HDAC1, affects its biological activity 
and, most importantly, suggest that specific reduction of HDAC1, or the use of pan-HDAC 
inhibitors, reduce TDP-43 induced cell-toxicity. Although we can only speculate on the 
molecular mechanisms underlying these phenomena, the evidence obtained in vivo and 
in vitro certainly create a good substrate to hypothesize future pharmacological tests. 
HDAC inhibitors were originally applied to cancer therapy and some of them, such as 
Panobinostat, have been approved from FDA for multiple myeloma treatment, while 
others, like VPA and SPB, are in clinical trials of phase III and II, respectively, for solid and 
hematological malignancies. At present more than 350 clinical trials have been carried out 
or are on-going involving HDACi not only as single therapeutic but also in combination 
with other targeted agents against various human diseases, including neurodegenerative 
diseases. VPA was approved by FDA in 1978 as an anticonvulsant drug for the treatment 
of seizure disorders, even if the molecular targets of these drugs were not known yet. The 
possibility of using HDACi for neurodegenerative treatment originates in 2008, when 
Hahnen identified two major HDACi neuroprotective mechanisms, including the 
transcriptional activation of disease-modifying genes and the rectification of 
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destabilization in histone acetylation homeostasis53. Several pan-HDAC inhibitors reduced 
ALS development in mice54, but, even if they were safe, tolerable and efficient in 
improving histone acetylation levels, they failed to ameliorate clinical parameters in ALS 
patients31. The translational failure can be due to lack of selectivity for different HDACs 
and to unwanted off-target effects and, for sure, more specific drugs should be 
developed. But it is worth to keep in mind the "edaravone story": only after a post-hoc 
analysis of a previous phase III study significant differences compared with placebo were 
highlighted in subset of ALS patients55. Therefore, considering that HDAC inhibition can be 
a precious therapeutic option, molecular characterization of TDP-43/HDAC1 functional 
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